

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 16:41:33 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Cowen Health Care Conference in Boston - China Pharma Market Panel - March 2, 2020 in Boston

Please RSVP no.

From: Scala, Steve <Steve.Scala@cowen.com>
Sent: Sunday, February 9, 2020 11:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Nadeau, Phil <Phil.Nadeau@cowen.com>; Miner, Kathy <Kathy.Miner@cowen.com>; Nedelcovych, Michael <Michael.Nedelcovych@cowen.com>
Subject: Cowen Health Care Conference in Boston - China Pharma Market Panel - March 2, 2020 in Boston

Hi Dr. Fauci

I am a pharmaceutical industry analyst at Cowen and Company, a New York City based investment company that specializes in health care. Each year we host a Health Care Conference in Boston in March that attracts 200+ companies and 1000+ investors. During this year's conference, we had planned to host a one-hour panel discussion on the evolution of and reforms within the China Health Care System and China Pharmaceutical market. However, given global concerns around Coronavirus, we have decided to focus the panel instead on the virus and the outlook for emerging treatments. This perspective is critical to health care companies and therefore the institutions that invest in them.

Our panel will take place during Cowen's 40th Annual Health Care Conference, which will be held at the Marriott Copley Place in Boston on March 2-4, 2020. We plan to host this panel on **Monday morning, March 2nd, between 9:05-10:05AM**. Attendees at our conference include institutional investors from insurance companies, mutual funds, pension funds, banks, and other types of funds, mainly in the U.S. and EU.

Cowen would provide you an honorarium for your time during the one-hour panel. **We propose an honorarium of \$1,500**, and we reimburse conference-related travel expenses.

The discussion will be Q&A only and no presentation on your part is requested.

We look forward to hearing from you.

Sincerely,

Steve Scala

In line with best practices suggested for brokerage firms, Cowen has a policy regarding our interaction with subject matter experts such as yourself, and by accepting and participating in this engagement, you agree to the conditions of this policy, including that you will not knowingly disclose any material non-public and/or confidential information; that your current employer permits you to participate in our event; that you are not employed by any of the companies anticipated to be discussed; and that your participation will not cause you to knowingly violate any contract (e.g., employment contract or consulting contract), agreement (e.g., confidentiality agreement) or other duty of confidentiality (e.g., serving on a board of directors) that you may have.

COWEN

Steve Scala

Pharmaceutical Industry Analyst
Equity Research

Cowen and Company, LLC
Two International Place, 28th Fl.
Boston, MA 02110
617-946-3923
steve.scala@cowen.com
www.cowen.com

This message and any attachments are confidential. If you are not the intended recipient, please notify the sender immediately and destroy this email. Any unauthorized use or dissemination is prohibited. All email sent to or from our system is subject to review and retention. Nothing contained in this email shall be considered an offer or solicitation with respect to the purchase or sale of any security in any jurisdiction where such an offer or solicitation would be illegal. Neither Cowen Inc. nor any of its affiliates ("Cowen") represent that any of the information contained herein is accurate, complete or up to date, nor shall Cowen have any responsibility to update any opinions or other information contained herein.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 16:41:04 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Podcast: Newt's World Ep 56: China's Coronavirus <http://bit.ly/2Sud2am>

Definitely for the Director's page

From: Folkers, Greg (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Sent: Sunday, February 9, 2020 9:45 AM
Subject: Podcast: Newt's World Ep 56: China's Coronavirus <http://bit.ly/2Sud2am>

Is the Coronavirus the next global pandemic or will the disease be eradicated in a short period of time? Newt's guests, Dr. Anthony Fauci and Dr. Peter Daszak, provide the information you need to know about the Coronavirus crisis.



Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: (b) (6)
Sent: Sun, 9 Feb 2020 10:53:02 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]
Subject: Fwd: CNNI Interview Request: Dr. Anthony Fauci,

Done

Begin forwarded message:

From: "Hynds, Joanna (NE)" <Joanna.Hynds@turner.com>
Date: February 9, 2020 at 9:49:21 AM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)
Cc: "Pfeifer, Hazel" <Hazel.Pfeifer@turner.com>, "Lovejoy, Hannah (NE)" <Hannah.Lovejoy@turner.com>, "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: RE: CNNI Interview Request: Dr. Anthony Fauci,

Hi Patricia,

I have let DC know, Angie will be there to greet him at 10.20a and bring him straight up.

DC Number: +1 202 5100172.

Best,

Joanna

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Sent: 09 February 2020 14:42
To: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
Cc: Pfeifer, Hazel <Hazel.Pfeifer@turner.com>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: CNNI Interview Request: Dr. Anthony Fauci,

We are good. 1030 am ET his is firm. He will arrive the wdc cnn studio at 820 am ET so if you can have someone meet him at the entrance lobby to get him upstairs quickly that would be helpful.

Sent from my iPhone

On Feb 9, 2020, at 9:39 AM, Hynds, Joanna (NE)
<Joanna.Hynds@turner.com>wrote:

Hi Patricia,

That would be perfect. I am so sorry on the miscommunication on my part.

We really appreciate you accommodating us at this short notice.

Best,

Joanna

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Sent: 09 February 2020 14:35
To: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
Cc: Pfeifer, Hazel <Hazel.Pfeifer@turner.com>; Lovejoy, Hannah (NE)
<Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E]
(b) (6)>
Subject: Re: CNNI Interview Request: Dr. Anthony Fauci,

Dr DrFauci can be there for a 1030 am hit

We need to know ASAP if this is firm and what the exact hit time

Sent from my iPhone

On Feb 9, 2020, at 9:26 AM, Hynds, Joanna (NE)
<Joanna.Hynds@turner.com>wrote:

Just wanted to let you know the Flash Studio will be **DC G Studio**
CAM 23

Our Bureau Address is
820 First ST NE
20002 Washington

Please contact the bureau at **+1-202-898-7911**

Please arrive at 10.40, you will be on around 11 – I will update with exact hit time as soon as I have it.

Best,

Joanna

From: Conrad, Patricia (NIH/NIAID) [E]

(b) (6)>

Sent: 09 February 2020 13:33

To: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>

Cc: Pfeifer, Hazel <Hazel.Pfeifer@turner.com>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Subject: Re: CNNI Interview Request: Dr. Anthony Fauci,

Adding Dr Fauci here

He can come to the WDC CNN studio. Please send us the exact live hit time as well as the studio address and on-site contact name, number and cell number ASAP. Dr Fauci cell is (b) (6) and you have mine.

Thank you.

Sent from my iPhone

On Feb 9, 2020, at 8:21 AM, Hynds, Joanna (NE) <Joanna.Hynds@turner.com> wrote:

Dear Patricia,

Just following up from our phone conversation, unfortunately I won't be able to facilitate a StudioGo truck for this interview.

We are still really keen to get Dr Fauci on the show – will he be able to come to the bureau?

I will be able to book him a car if he needs.

Let me know what suits,

Best,

Joanna

From: Conrad, Patricia (NIH/NIAID) [E]
[REDACTED] (b) (6)>
Sent: 09 February 2020 13:00
To: Hynds, Joanna (NE)
<Joanna.Hynds@turner.com>
Subject: Re: CNNI Interview Request: Dr. Anthony
Fauci,

For the trick- the location is northwest Washington
DC. Near American university.

Sent from my iPhone

On Feb 9, 2020, at 7:51 AM, Conrad,
Patricia (NIH/NIAID) [E]
[REDACTED] (b) (6)>wrote:

Please call me ASAP at [REDACTED] (b) (6)
for this request.

Sent from my iPhone

Begin forwarded message:

From: "Fauci, Anthony
(NIH/NIAID) [E]"
[REDACTED] (b) (6)
Date: February 9, 2020
at 7:08:54 AM EST
To: "Conrad, Patricia
(NIH/NIAID) [E]"
[REDACTED] (b) (6)
[REDACTED]
Subject: Fwd: CNNI
Interview Request: Dr.
Anthony Fauci,

Sent from my iPhone

Begin forwarded
message:

From:

"Hynds,
Joanna
(NE)"
<Joanna.Hynds@turner.com>

Date:

February
9, 2020 at
6:06:15
AM EST

To: "Fauci,
Anthony
(NIH/NIAID) [E]"

(b) (6)

Cc:

"Tejera,
Isabel
(Intern)"
<isabel.Tejera@turner.com>,
"Lovejoy,
Hannah
(NE)"
<Hannah.Lovejoy@turner.com

>

Subject:

**CNNI
Interview
Request:
Dr.
Anthony
Fauci,**

Dear Dr
Fauci,

I hope you
are well! I
am
reaching
out from
CNN
Internatio
nal to
enquire if
you are
available
today to
join us on
**Connect
the World**
at **11aET**
to discuss
the
coronavir
us.

Might this
be a
possibility
? It would
be great
to arrange
this.

Backgroun
d on CNN

- C
N
N
In
te
rn
ati
on
al
re
ac
he
s

m
or
e
th
an
25
0
mi
lli
on
ho
us
eh
ol
ds
w
or
ld
wi
de
in
cl
ud
in
g
in
th
e
U
S
vi
a
DI
RE
CT
V.
• C
N
N
In
te
rn
ati
on
al
is
th
e

nu
m
be
r
o
n
e
i
n
t
e
r
n
a
t
i
o
n
a
l
T
V
n
e
w
s
c
h
a
n
n
e
l
a
c
c
o
r
d
i
n
g
t
o
a
l
l
m
a
j
o
r
m
e
d
i
a
s
u
r
v
e
y
s
a
c
r
o
s
s
E
u
r
o
p
e
,
t
h
e
M
i
d
d

le
Ea
st
an
d
Af
ric
a,
th
e
As
ia
Pa
cif
ic
re
gi
on
an
d
La
tin
A
m
eri
ca

- In
Se
pt
e
m
be
r
20
19
C
N
ca
m
ha
d
16
2
mi
lli
on

un
iq
ue
re
ad
er
s
gl
ob
all
y
pe
r
m
on
th
an
d
11
4
mi
lli
on
m
ob
ile
re
ad
er
s
a
m
on
th
,
le
ad
in
g
th
e
BB
C,
Ya
ho
o
an
d

New York Times

Best,

**Joanna
Hynds**

**Planning
Desk
CNN
International**

+ 44 207
693 1640
(office)

(b) (6)

(b) (6) (cell)

joanna.hynds@turner.com

<image001.png>

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee

. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal

and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International

Limited
(Company
No.
5001368)
are
incorporat
ed in
England
and Wales
and share
the same
registered
office at
Turner
House, 16
Great
Marlboro
ugh
Street,
London
W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner

House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail

communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 13:05:06 +0000
To: Kaplan, Edward H
Cc: Redfield, Robert R. (CDC/OD); Cetron, Marty (CDC/DDID/NCEZID/DGMOQ); Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Subject: RE: Coronavirus containment modeling
Attachments: hcms_Wuhan_Feb7_2020_In_Press.pdf

Ed:

Many thanks for sending the manuscript. I hope that all is well with you.
Best regards,
Tony

-----Original Message-----

From: Kaplan, Edward H [REDACTED] (b) (6)>
Sent: Saturday, February 8, 2020 10:13 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: Coronavirus containment modeling

Dear Dr. Fauci,

It has been many years since we corresponded regarding smallpox bioterrorism and vaccination control.

The attached paper on containing a community coronavirus outbreak from a few initial cases via isolation and quarantine might interest you. The news is mostly good - isolation and quarantine can get the transmission rate below epidemic threshold - but the key is rapid detection of infected persons. Also discussed are some ideas for alleviating congestion in the hospital. I hope that you find it helpful.

Best, Ed Kaplan

Edward H. Kaplan, Ph.D.
William N. and Marie A. Beach Professor of Operations Research Professor of Public Health Professor of Engineering Yale School of Management Box 208200 New Haven, Connecticut 06520-8200

Phone: [REDACTED] (b) (6)
e-mail: [REDACTED] (b) (6)

<http://faculty.som.yale.edu/EdKaplan/>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 12:40:23 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: CNNI Interview Request: Dr. Anthony Fauci,

I will do this and if they can bring a truck to the house like they did last time, it was great. Let us discuss.

From: Hynds, Joanna (NE) <Joanna.Hynds@turner.com>
Sent: Sunday, February 9, 2020 6:06 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Cc: Tejera, Isabel (Intern) <isabel.Tejera@turner.com>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Subject: CNNI Interview Request: Dr. Anthony Fauci,

Dear Dr Fauci,

I hope you are well! I am reaching out from CNN International to enquire if you are available today to join us on **Connect the World** at **11aET** to discuss the coronavirus.

Might this be a possibility? It would be great to arrange this.

Background on CNN

- CNN International reaches more than 250 million households worldwide including in the US via DIRECTV.
- CNN International is the number one international TV news channel according to all major media surveys across Europe, the Middle East and Africa, the Asia Pacific region and Latin America.
- In September 2019 CNN.com had 162 million unique readers globally per month and 114 million mobile readers a month, leading the BBC, Yahoo and New York Times.

Best,

Joanna Hynds


Planning Desk

CNN International

+ 44 207 693 1640 (office)

+ [REDACTED] (b) (6) (cell)

joanna.hynds@turner.com



Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

From: (b) (6)
Sent: Sun, 9 Feb 2020 07:08:49 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: CNNI Interview Request: Dr. Anthony Fauci,

Sent from my iPhone

Begin forwarded message:

From: "Hynds, Joanna (NE)" <Joanna.Hynds@turner.com>
Date: February 9, 2020 at 6:06:15 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" <(b) (6)>
Cc: "Tejera, Isabel (Intern)" <isabel.Tejera@turner.com>, "Lovejoy, Hannah (NE)" <Hannah.Lovejoy@turner.com>
Subject: CNNI Interview Request: Dr. Anthony Fauci,

Dear Dr Fauci,

I hope you are well! I am reaching out from CNN International to enquire if you are available today to join us on **Connect the World** at **11aET** to discuss the coronavirus.

Might this be a possibility? It would be great to arrange this.

Background on CNN

- CNN International reaches more than 250 million households worldwide including in the US via DIRECTV.
- CNN International is the number one international TV news channel according to all major media surveys across Europe, the Middle East and Africa, the Asia Pacific region and Latin America.
- In September 2019 CNN.com had 162 million unique readers globally per month and 114 million mobile readers a month, leading the BBC, Yahoo and New York Times.

Best,

Joanna Hynds


Planning Desk

CNN International

+ 44 207 693 1640 (office)

+ (b) (6) (cell)

joanna.hynds@turner.com



Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 03:33:50 +0000
To: Janet Tobias
Subject: RE: Background question

Janet:

Nothing definite on this. To my knowledge, no one has specifically looked at real cross-reactivity although there have been speculation that because there is about 80-90% homology between nCoV and SARS that there may be some use of the mAbs made against SARS for nCoV. I have not seen any data where people took sera from patients with nCoV and checked if it neutralized SARS and vice versa.

Best,
Tony

-----Original Message-----

From: Janet Tobias <janet@ikanamedia.com>
Sent: Saturday, February 8, 2020 6:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Background question

Dear Tony; I have a background question as I am wading through reading as much as possible on the 2019 coronavirus. Do we know if the antibodies that can neutralize SARS are also effective against the 2019 coronavirus? I may be completely off track, but just trying to think through some things I am reading.

Janet

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 03:28:39 +0000
To: Lenardo, Michael (NIH/NIAID) [E]
Subject: RE: Hope you're doing well.

Thanks, Mike. Am hanging in there.

From: Lenardo, Michael (NIH/NIAID) [E] (b) (6) >
Sent: Saturday, February 8, 2020 5:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Hope you're doing well.

Hi Tony,

Was just leaving the lab and saw your car out in front of building 31. Hope you're doing well! I'm sure you're busy with the coronavirus crisis.

You continue to be my inspiration!

Best wishes, Mike

Michael Lenardo M.D.
NIH Distinguished Investigator
Chief, Molecular Development of the Immune System Section
Laboratory of Immune System Biology,
Director, Clinical Genomics Program,
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Building 10, Room 11D14
10 Center Drive, MSC 1892
Bethesda, MD 20892-1892 USA

Tel: (b) (6) (O); (b) (6) (M)
FAX: [301-402-8530](tel:301-402-8530)
Email: (b) (6)

ASSISTANT: Gloria Rodela

Tel: (b) (6)
Email: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 8 Feb 2020 20:54:52 +0000
To: (b) (6)
Subject: FW: Invite
Attachments: nejmoa2001316.pdf

Here it is. As discussed, let us re-read and convene sometime tomorrow to outline our approach.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Baden, Lindsey, M.D. <lbaden@nejm.org>
Sent: Saturday, February 8, 2020 12:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Invite

Tony,

As I am sure you are aware we recently web released the attached paper providing some initial estimates of key transmission parameters associated with nCoV-2019 virus. It will soon be coming out in a print issue and we would like an editorial to go with it. Might you be willing/interested in authoring such a piece? Our editorials are typically about 800 words with up to 10 references. As soon as you provide it to us we will web release it and then link it with the attached article in an upcoming print issue. Are you interested?

Please confirm no potential COIs.

Thank you for considering,
Lindsey

Lindsey R. Baden, MD
Deputy Editor
New England Journal of Medicine

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 8 Feb 2020 17:44:45 +0000
To: Robinson, Sae; Conrad, Patricia (NIH/NIAID) [E]
Cc: naugenstein@wtop.com
Subject: RE: request for info from WTOP's Neal Augenstein

Sae:

I assume that this is taken care of with the interview that I just gave for WTOP today
Thanks,
Tony

From: Robinson, Sae <srobinson@wtop.com>
Sent: Saturday, February 8, 2020 7:57 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: request for info from WTOP's Neal Augenstein

We will call at 11:20 am. Thank you both!

On Feb 8, 2020, at 07:52, Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
wrote:

Dr Fauci can be available for an interview between 11 am ET and 1130 am ET. Please call
him at (b) (6) back up cell at (b) (6)

What is the exact hit time?

Sent from my iPhone

On Feb 8, 2020, at 7:42 AM, Fauci, Anthony (NIH/NIAID) [E]
(b) (6)> wrote:

Sae:

Patty will get back to you today.

Best,
Tony

From: Robinson, Sae <srobinson@wtop.com>
Sent: Saturday, February 8, 2020 7:06 AM
To: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Fauci,

Anthony (NIH/NIAID) [E] (b) (6)

Subject: Re: request for info from WTOP's Neal Augenstein

Good morning.

I'd like to follow up on yesterday's inquiry from our reporter Neal.

If Dr. Fauci is available to address the concerns of this cruise ship in Japan with Corona virus (re: air circulation system) today, we'd love him to have him on.

Unfortunately, the first available interview time is after 11 a.m.

If it works, please let me know. This time, we'd like to record an interview to be used for air so we have some flexibility.

Thank you!

Sae Robinson
WTOP News
202-895-5060

On Feb 7, 2020, at 12:59, Augenstein, Neal
<naugenstein@wtop.com> wrote

Begin forwarded message:

From: "Conrad, Patricia (NIH/NIAID) [E]"
(b) (6)>
Date: February 7, 2020 at 12:17:40 PM EST
To: "Augenstein, Neal" <naugenstein@wtop.com>
Subject: RE: request for info from WTOP's Neal Augenstein

Dr Fauci asked that I respond – he is in back to back meeting today up until about 7 pm. If you want to speak with him tomorrow – we might be able to make that work

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director

National Institute of Allergy and Infectious
Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892

(b) (6)

301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Augenstein, Neal
<naugenstein@wtop.com>
Sent: Friday, February 7, 2020 8:29 AM
To: Fauci, Anthony (NIH/NIAID) [E]
(b) (6)>
Subject: request for info from WTOP's Neal Augenstein

Hi, Dr. Fauci. Hope you're well

Spoke with some passengers aboard the Diamond Princess cruise ship in Japan, where the number of coronavirus cases onboard are jumping. Can we do a brief interview re: thoughts on quarantining on board ship (with, I would assume a closed circulating air system) versus evacuating them?

I'm available at your earliest convenience. Or, if you'd like to just email some thoughts, that'd be great. Thanks and best.

Neal Augenstein

Reporter

103.5FM and wtop.com

Washington, DC

(b) (6) cell

202-895-5060 newsroom

naugenstein@wtop.com

Twitter: @AugensteinWTOP

Skype: WTOPNealAugenstein

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 8 Feb 2020 17:30:45 +0000
To: Awwad, David (NIH/NIAID) [C];Folkers, Greg (NIH/NIAID) [E]
Cc: NIAID OD AM
Subject: RE: David -- how do we put a link to the Coronavirus public folder on ASF' desktop?

Monday is fine.

From: Awwad, David (NIH/NIAID) [C] (b) (6) >
Sent: Saturday, February 8, 2020 12:11 PM
To: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Cc: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: Re: David -- how do we put a link to the Coronavirus public folder on ASF' desktop?

I will add Monday, unless you want me to connect now.

Sent from my iPhone

On Feb 8, 2020, at 11:42 AM, Folkers, Greg (NIH/NIAID) [E] <(b) (6)> wrote:

<image001.jpg>

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 8 Feb 2020 17:29:51 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Fox and Friends video -- US confirms first American coronavirus death / AS Fauci <http://bit.ly/2tLtgne>

Fyi. It came out well.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)
Sent: Saturday, February 8, 2020 11:34 AM
Subject: Fox and Friends video -- US confirms first American coronavirus death / AS Fauci <http://bit.ly/2tLtgne>



Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 8 Feb 2020 17:24:25 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: CNN Interview Request: Dr. Anthony Fauci

I believe that we can do this if they do it early in the 10:00 AM segment on Monday. We may also be able to encroach a bit on Diane Rehm's podcast (10:30) since I believe that this is taped. I leave this up to you and so please get back to them and work it out if you can. Jim Sciutto (b) (6). Thanks.

From: Griffin, Janelle <Janelle.Griffin@turner.com>
Sent: Saturday, February 8, 2020 11:33 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: CNN Interview Request: Dr. Anthony Fauci
Importance: High

Good morning Dr. Fauci,

I hope this email finds you doing well.

I'm reaching out on behalf of Newsroom w/Poppy Harlow & Jim Sciutto hoping you can join for an interview.

Are you available to join CNN this Monday February 10th in the 10a et hour?

This would be live for about 5-7 minutes to discuss developments regarding the coronavirus.

Please feel free to contact me via email or at (b) (6) to let me know.

Thanks for your time- I look forward to hearing from you soon.

Janelle Griffin-Butts
Editorial Producer, **CNN**
Email: janelle.griffin@turner.com | Twitter: @janellegCNN

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 8 Feb 2020 03:23:51 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Details for "Fox & Friends" Tomorrow (Saturday) LIVE at 8:30am ET

I am OK with their coming to the house without a truck. I will call you in the AM.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Friday, February 7, 2020 7:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Fwd: Details for "Fox & Friends" Tomorrow (Saturday) LIVE at 8:30am ET

Am at dinner. Will call u later

Sent from my iPhone

Begin forwarded message:

From: "Zuccaro, Alexandra" <Alexandra.Zuccaro@FOXNEWS.COM>
Date: February 7, 2020 at 7:16:21 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" (b) (6) >
Subject: RE: Details for "Fox & Friends" Tomorrow (Saturday) LIVE at 8:30am ET

They'll be at his house. Sorry, the truck wasn't available, but this will work just as well too!

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Friday, February 7, 2020 6:51 PM
To: Zuccaro, Alexandra <Alexandra.Zuccaro@FOXNEWS.COM>
Subject: [EXTERNAL] Re: Details for "Fox & Friends" Tomorrow (Saturday) LIVE at 8:30am ET

Will they set up outside his house or is this the trick that he goes into it for the interview?

Sent from my iPhone

On Feb 7, 2020, at 6:49 PM, Zuccaro, Alexandra
<Alexandra.Zuccaro@foxnews.com> wrote:

Hi Everyone,

Babu Aryankalayil is set to arrive at [REDACTED] (b) (6) around 7:30am/est tomorrow for our interview with Dr. Anthony Fauci. Babu, please give Dr. Fauci a call on his cell about 15 minutes before arrival. The IFB and PL Numbers are below. Please let us know if you have any questions, and please also let us know what REM this will be on.

"Fox & Friends"

DATE: Saturday, February 8th

CREW ARRIVAL TIME: 7:30am ET

ADDRESS: [REDACTED] (b) (6)

LIVE TALK BACK: 8:35am ET – 8:40am ET with Pete Hegseth, Emily Compagno, & Jason Chaffetz

Satellite Window: 0700-0800

GUEST: Dr. Anthony Fauci

TOPIC: CORONAVIRUS CRUISE SHIP LATEST

GUEST CONTACT: Dr. Anthony Fauci, [REDACTED] (b) (6) / Media contact Patricia Conrad cell: [REDACTED] (b) (6) cell: [REDACTED] (b) (6)

CREW CONTACT: Babu Aryankalayil, [REDACTED] (b) (6) / [REDACTED] (b) (6)

F&F NYC CONTACTS:

Technical Director: Todd Boone: Phone - [REDACTED] (b) (6) email: todd.boone@foxnews.com

F&F Control Room Contact: Tami Radabaugh, [REDACTED] (b) (6) email: Tami.Radabaugh@FOXNEWS.COM

PL: 800-369-5815, Camera and Tech: [REDACTED] (b) (4) Producers: [REDACTED] (b) (4)

IFB: 800-369-6719

ACQ and REM Coordinator: 212-301-3200

NY Transmission: 212-301-3100

NY Sat Desk (Bookings) 212-301-3400

A.M. Emergency Contact: Mary Carol Butterfield: Cell: [REDACTED] (b) (6) & NYC Greenroom (212) 301-1983 email: Mary.Butterfield@FOXNEWS.COM

Thanks,

Alexandra Zuccaro

"Fox & Friends"

Fox News Channel

1211 Avenue of the Americas, 2nd Floor

New York, NY 10036

Cell: [REDACTED] (b) (6)

Alexandra.Zuccaro@FOXNEWS.COM

This message and its attachments may contain legally privileged or confidential information. It is intended solely for the named addressee. If you are not the addressee indicated in this message (or responsible for delivery of the message to the addressee), you may not copy or deliver this message or its attachments to anyone. Rather, you should permanently delete this message and its attachments and kindly notify the sender by reply e-mail. Any content of this message and its attachments that does not relate to the official business of Fox News or Fox Business must not be taken to have been sent or endorsed by either of them. No representation is made that this email or its attachments are without defect.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 20:20:58 +0000
To: Mellors, John W
Cc: Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: Re: Important Brief Conversation
Attachments: image001.gif

I know. Glad we could work it out

On Feb 7, 2020, at 11:48 AM, Mellors, John W [REDACTED] (b) (6) > wrote:

Dear Tony,
Approval received from DHHS. The shipment of remdesivir to China is on it's way.
No need to connect.
Thanks,
John

From: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Sent: Thursday, February 6, 2020 7:04:53 PM
To: Mellors, John W [REDACTED] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] [REDACTED] (b) (6)
Subject: RE: Important Brief Conversation

John:
Please give me office a call tomorrow and they will set up a time to connect us.
Best,
Tony

From: Mellors, John W [REDACTED] (b) (6)
Sent: Thursday, February 6, 2020 5:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Cc: Mellors, John W [REDACTED] (b) (6) >
Subject: Important Brief Conversation

Dear Tony, Cliff

Could we speak briefly about an important international coronavirus trial that is in jeopardy?

My mobile phone number is [REDACTED] (b) (6)

John

John W. Mellors, M.D.
Chief, Division of Infectious Diseases
Distinguished Professor and Endowed Chair for Elimination of HIV and AIDS
University of Pittsburgh School of Medicine
Scaife Hall, Suite 818
3550 Terrace Street
Pittsburgh, PA 15261

Tel: (b) (6)

Fax: 412 383-7982

E-mail: (b) (6)

Visit our Division website: <http://www.dept-med.pitt.edu/ID/>

Read the "ID Pitt Stop" blog: <https://idpittstop.wordpress.com>

Like us

[<image001.gif>](#)



From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 15:37:53 +0000
To: (b) (6)
Subject: RE: NIH position on travel to Singapore???

Go to CDC website. There are no travel alerts for Singapore and so for now it is OK to travel there.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Friday, February 7, 2020 9:03 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Fwd: NIH position on travel to Singapore???

jim lynch is asking for sources of info for travel advice re: coronavirus. (b) (6) is planning to go to Singapore. any suggestions?

----- Forwarded message -----

From: James L (b) (6)>
Date: Thu, Feb 6, 2020 at 8:16 AM
Subject: NIH position on travel to Singapore???
To: (b) (6)

Hi (b) (6)

(b) (6) is scheduled to travel to Singapore on March 9th for a week.

What is the best source of up-to-date information and travel recommendations related to the coronavirus?

Thanks

Jim

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 10:46:54 +0000
To: NIAID OD AM
Subject: FW: Royal Society of Medicine london

Let us discuss.

-----Original Message-----

From: Ian Hosein [REDACTED] (b) (6)
Sent: Friday, February 7, 2020 5:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Royal Society of Medicine london

Hello Dr Fauci,

By way of introduction, I was Jim MacLowry's last fellow at the NIH and have been working in the UK since then as a medical microbiologist and hospital epidemiologist.

I am the lead medical microbiologist at the Royal Society of Medicine in the UK and was wondering about your availability please to speak at a conference on emergent Coronavirus threats to be held at the RSM on November 24th coming?

The RSM is a unique educational charity here and we have councils covering all aspects of healthcare. The program is still developing but I wanted to check on your availability quickly- we have an academic fund to which I can apply to cover your trip but will need to do so soon.

It was both exciting and inspirational being a senior staff fellow at the NIH - my background is international;

[REDACTED] (b) (6) and the international perspectives at the NIH were so encouraging. All non- American fellows recognised the national strategic remit of the NIH for the US , but I have often wondered if an assessment has ever been made of how fellows like myself have brought the spirit of that institution to other nations.

With kind regards,

Ian

Ian K Hosein MD FCAP FRCPath MBA
Royal Society of Medicine
London
Mobile [REDACTED] (b) (6)

Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:56:15 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Comment on NEJM details of "asymptomatic" contact in Germany
Attachments: nejmc2001468_appendix.pdf

Please set up a call. Happy to do over the weekend or Friday evening.

From: Ian Ingram <iingram@medpagetoday.com>
Sent: Thursday, February 6, 2020 1:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: Comment on NEJM details of "asymptomatic" contact in Germany

Hi Dr. Fauci,
I'm filling in for Molly Walker on the coronavirus beat while she's covering a meeting for *MedPage Today*, but I wanted to see if you could be available to offer your quick reaction to the Supplementary Index published today (attached) in the *New England Journal of Medicine* regarding the widely reported asymptomatic contact in Germany.

Looking at the patient's daily take on how she felt it's unclear to me whether this qualifies as symptomatic or not. I imagine this will be disputed.

Best regards,

- Ian

--

Ian Ingram
Deputy Managing Editor
MedPage Today LLC
(b) (6)
iingram@medpagetoday.com
medpagetoday.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:53:47 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: BuzzFeed News: 2019-nCoV vaccine development questions

Please set up a call with this person. Happy to do over the weekend.

From: Dan Vergano <dan.vergano@buzzfeed.com>
Sent: Wednesday, February 5, 2020 3:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Stover, Kathy (NIH/NIAID) [E] (b) (6)
Subject: BuzzFeed News: 2019-nCoV vaccine development questions

Dr. Fauci,

As you may recall, I'm a science reporter at BuzzFeed News. We wonder if you might have any perspective (or might recommend someone to comment) for a novel coronavirus story we are writing for this weekend, regarding vaccine efforts.

In short, we wonder how you see an eventual vaccine playing a role in the future of the outbreak? CDC has described the virus as not mutating as much as influenza -- does that suggest a vaccine would provide more than seasonal protection?

In the long term, we had a few other questions. Is this something you could see added to the MMR protocol for the general public, or only in regions where there are local outbreaks (is there an analogy to SARS or MERS vaccines in this contemplated use)? Is there any aspect of a race against time in vaccine development if this coronavirus is seasonal like influenza?

We are basically trying to understand where a vaccine fits into the future response to this new virus, we asked you these sort of questions about the Zika vaccine efforts and your perspective really helped a lot. Apologies for all the questions, if you had any perspective, we'd be grateful

Dan Vergano
BuzzFeed News
(b) (6)

cc: Kathy Stover

Dan Vergano | Science Desk (DC) | (b) (6)
BuzzFeed News
1630 Connecticut Ave, 7th Floor, Washington DC 20009
Send secure tips -- [contact.buzzfeed.com](https://www.buzzfeed.com/contact)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:45:34 +0000
To: Folkers, Greg (NIH/NIAID) [E]
Subject: RE: ASF / please see table from 1-29-2019 NEJM paper on Wuhan cases

Very interesting!!

From: Folkers, Greg (NIH/NIAID) [E] (b) (6) >
Sent: Thursday, February 6, 2020 2:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Doepel, Laurie (NIH/NIAID) [E] (b) (6) >; Eisinger, Robert (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6) >; Lerner, Andrea (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)
Subject: ASF / please see table from 1-29-2019 NEJM paper on Wuhan cases

Please see next to last line, which gives % of transmissions with “no exposure to either market or person with respiratory symptoms”

(b) (5)

[N Engl J Med](#). 2020 Jan 29. doi: 10.1056/NEJMoa2001316. [Epub ahead of print]

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia.

[Li Q¹](#), [Guan X¹](#), [Wu P¹](#), [Wang X¹](#), [Zhou L¹](#), [Tong Y¹](#), [Ren R¹](#), [Leung KSM¹](#), [Lau EHY¹](#), [Wong JY¹](#), [Xing X¹](#), [Xiang N¹](#), [Wu Y¹](#), [Li C¹](#), [Chen Q¹](#), [Li D¹](#), [Liu T¹](#), [Zhao J¹](#), [Li M¹](#), [Tu W¹](#), [Chen C¹](#), [Jin L¹](#), [Yang R¹](#), [Wang Q¹](#), [Zhou S¹](#), [Wang R¹](#), [Liu H¹](#), [Luo Y¹](#), [Liu Y¹](#), [Shao G¹](#), [Li H¹](#), [Tao Z¹](#), [Yang Y¹](#), [Deng Z¹](#), [Liu B¹](#), [Ma Z¹](#), [Zhang Y¹](#), [Shi G¹](#), [Lam TTY¹](#), [Wu JTK¹](#), [Gao GF¹](#), [Cowling BJ¹](#), [Yang B¹](#), [Leung GM¹](#), [Feng Z¹](#).
DOI:[10.1056/NEJMoa2001316](#)

Table 1. Characteristics of Patients with Novel Coronavirus–Infected Pneumonia in Wuhan as of January 22, 2020.*

Characteristic	Before January 1 (N = 47)	January 1 –January 11 (N = 248)	January 12 –January 22 (N = 130)
Median age (range) — yr	56 (26–82)	60 (21–89)	61 (15–89)
Age group — no./total no. (%)			
<15 yr	0/47	0/248	0/130
15–44 yr	12/47 (26)	39/248 (16)	33/130 (25)
45–64 yr	24/47 (51)	106/248 (43)	49/130 (38)
≥65 yr	11/47 (23)	103/248 (42)	48/130 (37)
Male sex — no./total no. (%)	31/47 (66)	147/248 (59)	62/130 (48)
Exposure history — no./total no. (%)			
Wet market exposure	30/47 (64)	32/196 (16)	5/81 (6)
Huanan Seafood Wholesale Market	26/47 (55)	19/196 (10)	5/81 (6)
Other wet market but not Huanan Seafood Wholesale Market	4/47 (9)	13/196 (7)	0/81
Contact with another person with respiratory symptoms	14/47 (30)	30/196 (15)	21/83 (25)
No exposure to either market or person with respiratory symptoms	12/47 (26)	141/196 (72)	59/81 (73)
Health care worker — no./total no. (%)	0/47	7/248 (3)	8/122 (7)

* Reduced denominators indicate missing data. Percentages may not total 100 because of rounding.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:38:45 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Latest

Please set up a call with David for the weekend.

From: davidwillman [REDACTED] (b) (6)
Sent: Thursday, February 6, 2020 2:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Subject: Latest

Hi Tony,

I know you must be swamped by matters related to the coronavirus. Nonetheless, I'd really like to confer, even if briefly. Would you have any window by phone today, over the weekend or next week? I'll also call Kim Barasch, per your recent guidance.

I'm researching an article that will chiefly explore the status of the Defense Department's advanced development and manufacturing facility in Alachua, Florida. On a related note, I'm also curious re the three HHS/BARDA facilities.

Best, David

David Willman
Washington Post
202-334-7081 –desk
[REDACTED] (b) (6) –mobile
301-656-3401 --alternate desk
david.willman@washpost.com
[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:11:47 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Reporter working on coronavirus vaccine story

Let us discuss. Maybe over the weekend

From: Morris, Amanda <Amanda.Morris@gannett.com>
Sent: Thursday, February 6, 2020 4:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED]> (b) (6)
Subject: Reporter working on coronavirus vaccine story

Hi Anthony,

I hope this email finds you well! My name is Amanda Morris and I'm a bioscience reporter at the Arizona Republic, part of the USA Today network. I'm reaching out because I'm currently working on a story about how some ASU researchers (Brenda Hogue, Bert Jacobs and Shawn Chen) are trying to develop strategies to make a vaccine against the new coronavirus as well as a general platform they can use in the case of future new coronavirus strain outbreaks in humans.

I know globally there are many researchers trying to develop a vaccine for this new coronavirus, and that the NIH is working with Moderna to do so – and hopes to start testing with in a few months. I'm wondering if I can talk to you over the phone and ask a few questions about the work that NIH is doing, and what the broader challenges are for developing a vaccine? I'd like to have broader context about vaccines for our readers.

Please let me know as soon as possible. You can call or text me at [REDACTED] (b) (6) Thank you!

All my best,
Amanda Morris

Bioscience Reporter for The Arizona Republic

Work phone: 602-444-8739

After hours and weekends, you can call or text my cell: [REDACTED] (b) (6)

Email: amorris@gannett.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:04:53 +0000
To: Mellors, John W
Cc: Conrad, Patricia (NIH/NIAID) [E]; Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Important Brief Conversation

John:

Please give me office a call tomorrow and they will set up a time to connect us.

Best,
Tony

From: Mellors, John W [REDACTED] (b) (6)
Sent: Thursday, February 6, 2020 5:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[REDACTED] (b) (6)>
Cc: Mellors, John W [REDACTED] (b) (6)
Subject: Important Brief Conversation

Dear Tony, Cliff

Could we speak briefly about an important international coronavirus trial that is in jeopardy?

My mobile phone number is [REDACTED] (b) (6)


John

John W. Mellors, M.D.
Chief, Division of Infectious Diseases
Distinguished Professor and Endowed Chair for Elimination of HIV and AIDS
University of Pittsburgh School of Medicine
Scaife Hall, Suite 818
3550 Terrace Street
Pittsburgh, PA 15261

Tel: [REDACTED] (b) (6)
Fax: 412 383-7982

E-mail [REDACTED] (b) (6)

Visit our Division website: <http://www.dept-med.pitt.edu/ID/>
Read the "ID Pitt Stop" blog: <https://idpittstop.wordpress.com>

Like us 

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:01:07 +0000
To: Howard Bauchner
Subject: RE: Subtitled Coronavirus Video

Howard:

Thanks for the feedback.

Best,
Tony

From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Sent: Thursday, February 6, 2020 6:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: FW: Subtitled Coronavirus Video

Tony

First live stream/podcast now with Chinese interpretation. URL below.

Second live stream/podcast will be put up tomorrow. URL below.

Couple big thank yous from prominent science writers – NYT/WSJ – said learned more listening to you for 30 minutes then everything they read in the last few weeks.

My response when you have a very wise scientist, who hears the question and answers the question, and has 40+ years of experience we should listen and learn.

Be well.

HCB

Howard Bauchner, MD
Editor in Chief of JAMA and the JAMA Network

Please respect the confidentiality of this email

Listen to my [chats with authors](#)

From: Karen Adams-Taylor <Karen.Adams-Taylor@ama-assn.org>
Date: Thursday, February 6, 2020 at 4:59 PM
To: Howard Bauchner <Howard.Bauchner@jamanetwork.org>, Annette Flanagin <Annette.Flanagin@jamanetwork.org>, Michael Berkwits <Michael.Berkwits@jamanetwork.org>, Tom Easley <Tom.Easley@ama-assn.org>, Brian Shields <Brian.Shields@ama-assn.org>, Betsy Solaro <Elizabeth.Solaro@ama-assn.org>, Sean O'Donnell

<Sean.O'Donnell@ama-assn.org>, Tiffany Jones <Tiffany.Jones@ama-assn.org>

Subject: Subtitled Coronavirus Video

The 1/27 Fauci subtitled video is now live: <https://jamanetwork.com/journals/jama/pages/coronavirus-alert> The 2/6 Fauci update video will go to the translator tomorrow.

-Karen

.....

Karen Adams-Taylor

Vice President, Publishing Production Operations

JAMA Network™

330 N Wabash Ave, Ste 39300, Chicago, IL 60611

T [REDACTED] (b) (6)

jamanetwork.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:00:35 +0000
To: Greg Folkers (b) (6); Billet, Courtney (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Subtitled Coronavirus Video

fyi

From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Sent: Thursday, February 6, 2020 6:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: FW: Subtitled Coronavirus Video

Tony

First live stream/podcast now with Chinese interpretation. URL below.

Second live stream/podcast will be put up tomorrow. URL below.

Couple big thank yous from prominent science writers – NYT/WSJ – said learned more listening to you for 30 minutes then everything they read in the last few weeks.

My response when you have a very wise scientist, who hears the question and answers the question, and has 40+ years of experience we should listen and learn.

Be well.

HCB

Howard Bauchner, MD
Editor in Chief of JAMA and the JAMA Network

Please respect the confidentiality of this email

Listen to my [chats with authors](#)

From: Karen Adams-Taylor <Karen.Adams-Taylor@ama-assn.org>
Date: Thursday, February 6, 2020 at 4:59 PM
To: Howard Bauchner <Howard.Bauchner@jamanetwork.org>, Annette Flanagin <Annette.Flanagin@jamanetwork.org>, Michael Berkwits <Michael.Berkwits@jamanetwork.org>, Tom Easley <Tom.Easley@ama-assn.org>, Brian Shields <Brian.Shields@ama-assn.org>, Betsy Solaro <Elizabeth.Solaro@ama-assn.org>, Sean O'Donnell <Sean.O'Donnell@ama-assn.org>, Tiffany Jones <Tiffany.Jones@ama-assn.org>
Subject: Subtitled Coronavirus Video

The 1/27 Fauci subtitled video is now live: <https://jamanetwork.com/journals/jama/pages/coronavirus-alert> The 2/6 Fauci update video will go to the translator tomorrow.

-Karen

.....

Karen Adams-Taylor

Vice President, Publishing Production Operations

JAMA Network™

330 N Wabash Ave, Ste 39300, Chicago, IL 60611

T [REDACTED] (b) (6)

jamanetwork.com

From: (b) (6)
Sent: Thu, 6 Feb 2020 15:09:43 -0500
To: Folkers, Greg (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Subject: Re: ASF --- Morens + Daszak +Taubeneberger paper

I agree. I will not be a co-author

On Feb 6, 2020, at 1:59 PM, Folkers, Greg (NIH/NIAID) [E]
(b) (6) wrote:



So the question to you – do you want to be part of this? ie be a coauthor

I would vote no – it wud look weird to add you as a coauthor now. Plus, plate too full.....

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 17:36:11 +0000
To: [REDACTED] (b) (6)
Cc: [REDACTED] (b) (6)
Subject: RE: nCoV: Heads-up

Thanks, Jim.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [REDACTED] (b) (6)
Sent: Thursday, February 6, 2020 10:33 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)
Cc: [REDACTED] (b) (6)
Subject: nCoV: Heads-up

Tony : As per below, we wanted to give you a heads up that [REDACTED] (b) (4)
[REDACTED]
[REDACTED]. We will keep you updated. Best. John and Jim

[French drugmaker Sanofi working on coronavirus initiative](#)

CHINA-HEALTH/SANOFI (PIX):French drugmaker Sanofi working on coronavirus initiative

PARIS, Feb 6 (Reuters) - French drugmaker Sanofi will announce a new coronavirus initiative within the next two weeks, its chief executive said on Thursday, adding that it wants to present something concrete and not add to "fantasies".

At least a dozen drugmakers are working on vaccines or antivirals to help those infected with the fast-spreading virus that has killed more than 500 people in China, but several have warned that development of treatments will take time.

"We have seen a flurry of activities from other companies," CEO Paul Hudson told a news conference after Sanofi published 2019 results on Thursday.

"We are one of the few companies that has the expertise to know when it is just a fantasy, or when it could be real. In the next week or two, you will see something more confirmatory about the approach we will take."

Hudson declined to give further details.

Sanofi had already said it was sharing its expertise and data acquired from other outbreaks with the Coalition for Epidemic Preparedness Innovations (CEPI), which is working with biotech businesses to try to develop a vaccine candidate for the coronavirus.

Britain's GlaxoSmithKline is also collaborating with CEPI.

"The objective here is not a newspaper headline, it is real work that will make a difference," Hudson said.

(Reporting by Matthias Blamont Writing by Sarah White Editing by David Goodman)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 16:28:04 +0000
To: hiattf@washpost.com
Cc: Redfield, Robert R. (CDC/OD);Fauci, Anthony (NIH/NIAID) [E]
Subject: Proposed OpEd
Attachments: Redfield and Fauci - Coronavirus OpEd - 02-06-2020 - FINAL.docx

Fred:

I hope that all is well with you. [REDACTED] (b) (6)

[REDACTED] (b) (6). Within this context, Bob Redfield and I have written an OpEd on the government response to the novel coronavirus outbreak. Would the *Post* have any interest in this? Many thanks.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [REDACTED] (b) (6)
FAX: (301) 496-4409
E-mail: [REDACTED] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 14:34:57 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E]
Subject: RE: Requested coronavirus talking points for press conference
Attachments: Talking Points for NIAID Director Dr. Fauci - press conference - 02-06-2020 - Fauci Press remarks with tracked edits.docx

Oooops! Forgot the attachment. Here it is.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thursday, February 6, 2020 9:34 AM
To: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6)
Subject: RE: Requested coronavirus talking points for press conference

Here is my revised and updated press remarks with my tracked edits showing. Please accept edits, do a spell and grammar check and resubmit. Also, put a copy in my folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Thursday, February 6, 2020 9:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6)
Subject: FW: Requested coronavirus talking points for press conference

HHS has asked us for your talking points for the press conference by 11am. We were planning to resubmit these. As was the case last time, this is a placeholder for the WH to know the outlines of what you would say. This is not a script.

Is it OK for us to send this to Bill?

From: Selgrade, Sara (NIH/NIAID) [E] (b) (6)>
Sent: Thursday, February 6, 2020 8:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6)
Subject: Requested coronavirus talking points for press conference

Dr. Fauci,

Attached please find the requested talking points from your last coronavirus press conference.

Please let us know if you need anything else.

Thanks,
Sara

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 10:58:13 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Cassetti, Cristina (NIH/NIAID) [E];Erbelding, Emily (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Follow up on Addis Meeting

Francis:

Thanks for the note. Best to have Trevor have his program person who will be leading this effort contact Cristina Cassetti in DMID. Cristina and Emily Erbelding could do all of the necessary and appropriate coordination.

Thanks,
Tony

From: Collins, Francis (NIH/OD) [E] (b) (6)
Sent: Thursday, February 6, 2020 4:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: FW: Follow up on Addis Meeting

See reference to coronavirus research in the note from Trevor. How would you like to coordinate this?

FC

From: Trevor Mundel (b) (6) >
Sent: Wednesday, February 5, 2020 10:55 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)
Cc: Eiss, Robert (NIH/FIC) [E] (b) (6); Glass, Roger (NIH/FIC) [E] <(b) (6)>; Kedest Tesfagiorgis <(b) (6)>
Subject: Re: Follow up on Addis Meeting

That would be great Francis. You might have seen our announcement this morning on the Coronavirus reponse funding and \$60M of the 100 is for R&D especially therapeutics rather than vaccines so we might want a quick call in the next few days to think about how we coordinate this - I've been in touch with Jeremy as well. Trevor

Trevor Mundel, MD, PhD
President, Global Health Program

V (b) (6)

F +1.206.494.7041

E (b) (6)

(b) (6)

Executive Assistant
Office of the President, Global Health

V (b) (6)
M (b) (6)
E (b) (6)
Bill & Melinda Gates Foundation
www.gatesfoundation.org

From: Collins, Francis (NIH/OD) [E] (b) (6) >
Sent: Wednesday, February 5, 2020 3:11 PM
To: Trevor Mundel
Cc: Eiss, Robert (NIH/FIC) [E]; Glass, Roger (NIH/FIC) [E]
Subject: RE: Follow up on Addis Meeting

Hey Trevor,

This is an excellent development. How about I send you a proposal of possible CARI TPs for Elioda – in the next 24 hours?

Francis

From: Trevor Mundel (b) (6)
Sent: Wednesday, February 5, 2020 4:43 PM
To: Tumwesigye Elioda (b) (6) >; Collins, Francis (NIH/OD) [E] (b) (6) >
Cc: (b) (6)
Subject: Re: Follow up on Addis Meeting

That's great to hear Elioda and congratulations, many thanks for letting us know. We will certainly get back to you shortly to enlist your help with the CARI initiative at AU level.

Warm regards,
Trevor

From: Tumwesigye Elioda (b) (6) >
Sent: Wednesday, February 5, 2020 1:16 PM
To: Trevor Mundel; Francis Collins
Cc: (b) (6)
Subject: Follow up on Addis Meeting

Dear Trevor,

Greetings from Uganda and indeed Africa. It was pleasure meeting you at the Grand Challenges Meeting in Ethiopia late last year. While there you, Francis Collins and I among others discussed the CARI Initiative and the need to support research, entrepreneurship and innovation in a big way in Africa. We also explored the mechanism for CARI Funding. We were also looking for a mechanism to reach the Committee of Ten (C10) Heads of State and Government championing Education, Science and Technology in Africa.

Well allow me to inform you that on 13th Dec 2019, I was elected to chair for 2 years the Ministers of Education and of Science and Technology in all the 55 Members States in Africa. We do this under the Specialized Technical Committee on Education, Science and Technology (STC-EST). This Saturday on 8th Feb in Addis, as chair of the ST -EST I will attend and speak at the Meeting of the above-mentioned C10.

The purpose of this message is to let you know of my added responsibilities and related opportunities as well as seek for any update or latest information regarding the CARI initiative. I look forward to intensified communication and collaboration.

Regards

Dr. Elioda Tumwesigye
Minister Science, Technology and Innovation
Republic of Uganda
Tel: [REDACTED] (b) (6)

Sent from my iPad

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 04:10:50 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Pandemic Threat Reduction

Similar e-0mail from Dr. Tubb.

From: Richard Tubb (b) (6) >
Sent: Thursday, January 30, 2020 11:35 AM
To: (b) (6) Fauci, Anthony (NIH/NIAID) [E]
(b) (6)
Subject: Fwd: Pandemic Threat Reduction

Good morning Tony.

Given your most recent appointment, I wanted to show you the courtesy of letting you know what I have already provided to senior leaders at the White House regarding a possible mitigating strategy until the definitive solution to the CoV is available and implemented. The string below includes additional information as to how titanium dioxide can fit into both the White House and the National/International solutions, and the open-source website for the company. Please keep in mind that because this product is already approved and in use in the EU for a variety of commercial uses, the data provided does not specifically address the applications I, and you, are interested in. However, with a deep understanding of the White House mission, I can say that there is not a big leap in that thought migration.

Dr. Jackson has already provided the same material to some of your White House Commission colleagues. I will also be reaching out to another friend of mine from the Bush-now-Trump Administration, Steve Biegun.

I encourage your representatives to meet with the company leadership and scientists while they are in the US next week. Please let me know if you have any questions that I can address. Thank you for once again stepping up to the plate for our Country.

v/r

Dick

ps...I remembered this morning where you and I last spoke--Bush (41) funeral.

----- Forwarded message -----

From: **Richard Tubb** [REDACTED] (b) (6) >

Date: Thu, Jan 30, 2020 at 8:54 AM

Subject: Re: Pandemic Threat Reduction

Good morning Gentlemen,

I just spoke with Ronny and believe I need to offer A relevant update and one point of explanation.

First, the company's joint venture partner in India is meeting with the Indian government as we speak. It appears likely that in light of the news of India's introduction to the corona virus the government will utilize their "National Catastrophe Budget" to expedite the funding necessary to secure and execute a contract with this company.

Secondly, I will attach the open source web site for the company to provide you background information that, out of respect for your time and for the sake of brevity, I left out of yesterday's note. It's important to note a couple of things:

This product is already proved and is in use in the EU with all the approvals appropriate for the same.

Secondly, in our language, this is a "standoff productr"—i.e. you apply it once and it continues to decontaminate and disinfect in the background for up to 1-5 years before retreating. (Depending on the type of use, normal daily cleaning using their cleaning solution—that is cheaper and more effective than what the application normally would use, e.g. in a hotel—continues). The chemical treats anything organic, i.e. bacteria, viruses, VOC, bio threats, etc. because it is a catalyst, it is neither used up, nor

does it produce microbial resistance or superbugs. It decontaminates and disinfects surfaces (e.g, airplanes and government critical infrastructures) and the air around the surface (and HVAC filters and air handlers).

The leadership will be in DC next week. I highly encourage any and all potential stakeholders make time to meet with them while they are here. To that end, I had already emailed Dr. Fauci (with whom I worked a great deal on similar challenges during the Bush Administration) before the announcement of his participation on the new coronavirus commission, I will also reach out to an old friend and colleague Steve BIEGUN now that he is in the commission. Please feel free to forward the information to others as you deem appropriate.

Thanks,

Dick Tubb

<https://act.global/>

Ps...once again, in my haste to get this to you, via iPad, please forgive typos and other apparent crimes against the dictionary.

Sent from my iPad

On Jan 29, 2020, at 3:15 PM, Richard Tubb (b) (6) > wrote:

Gentlemen, Brothers, and Others...

This is Dick Tubb, writing on behalf of Admiral Jackson and Dr. Hofmann (both copied herein). It feels like "old times"--I'm undecided as to whether they are good old times, or otherwise. Regardless, it does feel like we've been down a very similar road before. Perhaps we can apply some of the lessons-learned to the inevitable problems ahead.

In light of the current and evolving threat presented by the corona virus, I am writing to you as a courtesy to inform you of a project that Admiral Jackson, Dr. Hofmann, and I have been consulting on. We believe so strongly in the technology, people, and potential that we have been consulting pro bono and currently have no financial stake in the project. While not developed specifically designed for such purposes, I increasingly believe that until a vaccination and treatment for the corona virus is available, this technology may be the last best chance in containing, and eradicating the virus, thereby protecting the homeland, our economy, the Continuity of the Presidency, an Enduring Constitutional Government, our people and our Country. Moreover, reverting to my "lessons-learned, problems-ahead" statement, even after this crisis is over, and a vaccine and treatment procured, it will only be a matter of time until "next time." This letter is proof-positive of that reality. My experiences, especially in the early 2000's (e.g. anthrax and other biothreats, SARs, etc.) underpin my beliefs.

The technology that provides the solution, both now and in the future, involves a unique formulation of a photo catalytic

nano titanium dioxide solution (the Air Force guys will, of course, understand what that means, so you non-Air Force folks, just buy them a beer and they'll explain it to you) that is safer, more effective, and more cost effective than any other solution. It was developed and approved in the EU, and I have asked the senior leadership of the company to come to Washington DC next week. Dr. Hofmann and I spent the day yesterday with a Chinese "titan" respected by and with access to the most senior government officials, academic and medical giants, and investment and industry captains. I have encouraged, and he has agreed in principal, to follow our recommendations as they relate to their largest airline, and their key facilities.

In short, our strategic priority is to first fortify the weak link in the pandemic chain: the airlines. Doing so will provide the time necessary to isolate, contain, and ultimately destroy the threat at its source (Wuhan), and in its home (China). As President Bush so commonly stated about a very different threat, we need to fight the battle over there, so that we don't have to fight the battle here. Although President Bush was a true believer in the threat of a pandemic, I believe this threat, and the

threats that are surely to follow are, in reality, many, many times greater than the threat he envisioned when making that statement. By fighting a possible impending pandemic at its source we will preserve and protect the safety and confidence of our people, and the strength of our economy.

Once we have interrupted the threat supply chain, we can then shore up our critical infrastructure using the same technology and process, then assist the Chinese in addressing their challenges, and protect our international allies elsewhere. In that vein, in addition to the Chinese, I have also discussed this technology and strategy with senior proxies for another of my former patients, His Royal Highness, the Crown Prince of Saudi Arabia, and his father, the King.

As I noted above, I have asked the leadership of the company to come to Washington (from Germany and Denmark) next week for a variety of meetings. While Admiral Jackson will be "tied up in Texas" for the foreseeable future, please let me know if you would like to meet with myself or Dr. Hofmann, or the company

leadership while they are here, to learn more.

Thank you and my best to you all as you plan for and continue to protect our Country,

Very Respectfully,

Dick Tubb

ps. For your SA, I have also attached below the latest sit rep on the coronavirus.

--

Richard J. Tubb, MD
Brigadier General (retired)
White House Physician Emeritus

Shoreland's *Travax News Alert Service*— Abbreviated

China: More than 2,800 Cases of 2019-nCoV in 30 Provinces/Municipalities, Mainly in Wuhan; Cases Exported to 16 Countries

WHAT'S NEW

According to regional health authorities, more than 1,800 additional, confirmed cases (including 25 deaths) of pneumonia caused by 2019 novel coronavirus (2019-nCoV) have been reported since January 27, 2020, throughout the country, mainly in the provinces of Hubei (1,291), Guangdong (207), Zhejiang (173), Henan (168), and Hunan (143) and in the cities of Chongqing (132), Beijing (19), and Shanghai (13). Most new cases had a travel history to Wuhan. Almost all the recent deaths occurred in Hubei Province. Twenty more patients have recovered and been

discharged. More than 4,600 confirmed cases (including > 100 deaths) have occurred since December 8, 2019.

A total of 13 additional, exported, confirmed cases have been reported (through January 28, 2:00 p.m. EST) since Monday, January 27. More than 25 cases have been exported in the past 7 days. Cases reported since Monday arrived in the following countries on the dates shown: Singapore (January 19 and 23), Taiwan (January 22), Japan (January 20 and 21), France (arrival date unknown), and Thailand (arrival dates unknown). All of these cases had travel history to Wuhan or contact with an ill person from Wuhan while in China.

In addition to these exported cases, 7 locally acquired cases have been reported since Monday in Germany (4), Japan, Taiwan and Vietnam. The cases in Japan, Taiwan, and Vietnam reported contact with an obviously ill person from China. In Germany all 4 cases had close contact in a business seminar with an apparently asymptomatic Chinese woman on January 21 (who previously had contact with relatives from Wuhan); the woman states symptom onset was on a flight to Shanghai on January 23, and she was later confirmed to have 2019-nCoV. Incubation periods in these cases have been as short as 3 days. In light of the secondary cases in Germany in a business setting, the most cautious approach of having arrivals stay at home or in a hotel for 14 days after their last possible exposure in China is increasingly justified.

Updated travel advisories include: 1) Australia: reconsider travel to China; 2) Canada: avoid all travel to Hubei Province; 3) Finland: avoid nonessential travel to Hubei Province; 4) France: avoid all travel to Hubei Province; 5) Germany: avoid nonessential travel to China and avoid all travel to Hubei Province; 6) India: avoid all nonessential travel to China; 7) New Zealand: avoid all travel to Hubei Province; 8) Taiwan: avoid all nonessential travel to China.

Singapore now denies entry to residents of Hubei Province and those who have traveled there in the past 14 days.

Mongolia and 3 regions (Amur Oblast, Khabarovsk Kray, Yevreyskaya Oblast) in Far Eastern Federal District, Russia have closed their land borders with China.

Bangladesh, Canada, India, Kazakhstan, Russia, and South Korea are arranging flights to repatriate their respective citizens from Wuhan. These persons will be closely monitored and present little threat of onward transmission.

All tourist attractions in Tibet Autonomous Region have been closed.

Current influenza vaccination is recommended to decrease the risk of simple influenza being mistaken for 2019-nCoV upon return.

Infection control supplies have been depleted in medical facilities in the smaller cities in central China; the situation is critical in many areas and resupply is uncertain.

OVERALL RISK ASSESSMENT

The epidemic in China is months from peaking. A report indicates that just prior to the cordoning off of Wuhan, over 5 million residents (many potentially infectious) left for other parts of China, and many thousands left for Hong Kong, Singapore, Thailand, and Japan. Exported cases have so far been to countries likely to be capable of controlling (but not preventing) ongoing transmission, which will inevitably occur. In light of the secondary cases in Germany in a business setting, the most cautious approach of having arrivals stay at home or in a hotel for 14 days after their last possible exposure in China is increasingly justified.

Based on increasing data on virology, clinical presentation, and transmission, this coronavirus closely resembles SARS-CoV in many behaviors. Fortunately, sequential sequencing of viral isolates over time indicate no significant new viral mutations; mutations often increase transmission or virulence. WHO assesses the risk of this event to be very high in China, high at the regional level, and high at the global level. The closing of Wuhan airport and the major cities of Hubei province have yet to stem the flow of exported cases. The originally implicated animal market, now closed indefinitely, bears little relevance to the ongoing situation. Whether the market was the focus of a species jump from animals to humans or merely one of multiple amplification settings for initial cases is increasingly unclear. The degree of human-to-human spread outside of Hubei province remains unclear. A reproductive number, R_0 , is estimated at 1.4–2.5 by Chinese authorities and up to 5.5 by other scientists. An R_0 greater than 1 indicates that each case leads to more than 1 subsequent case, making control much more difficult. The spectrum of disease manifestations in a large cohort study has yet to be disclosed; a severe case rate of 20% has been consistent. The existence of mildly symptomatic and asymptomatic infectious cases could increase the risk of global spread. Case fatality is impossible to ascertain at present, and lesser or greater clinical virulence compared to MERS-CoV or SARS-CoV remains speculative.

See [2019 Novel Coronavirus Outbreak](#) for detailed information.

© 2020 Shoreland, Inc. All rights reserved.

Travax News Alert items are incorporated into Shoreland's subscriptions. Travax content represents decision-relevant, expert synthesis of real-time data reconciled with new and existing available advice from authoritative national and international bodies.

For email service changes, please forward this message to service@shoreland.com with your request. If the change should apply to all email subscriptions (Content Changes, Literature Watch and News Alert), please specify that in your request. [Account: SI53213; Recipient: bg.richard.tubb@gmail.com]

2019 Novel Coronavirus Outbreak Report— comprehensive

Last updated January 28, 2020.

What's New

According to regional health authorities, more than 1,800 additional, confirmed cases (including 25 deaths) of pneumonia caused by 2019 novel coronavirus (2019-nCoV) have been reported since January 27, 2020, throughout the country, mainly in the provinces of Hubei (1,291), Guangdong (207), Zhejiang (173), Henan (168), and Hunan (143) and in the cities of Chongqing (132), Beijing (19), and Shanghai (13). Most new cases had a travel history to Wuhan. Almost all the recent deaths occurred in Hubei Province. Twenty more patients have recovered and been discharged. More than 4,600 confirmed cases (including > 100 deaths) have occurred since December 8, 2019.

A total of 13 additional, exported, confirmed cases have been reported (through January 28, 2:00 p.m. EST) since Monday, January 27. More than 25 cases have been exported in the past 7 days. Cases reported since Monday arrived in the following countries on the dates shown: Singapore (January 19 and 23), Taiwan (January 22), Japan (January 20 and 21), France (arrival date unknown), and Thailand (arrival dates unknown). All of these cases had travel history to Wuhan or contact with an ill person from Wuhan while in China.

In addition to these exported cases, 7 locally acquired cases have been reported since Monday in Germany (4), Japan, Taiwan, and Vietnam. The cases in Japan, Taiwan, and Vietnam reported contact with an obviously ill person from China. In Germany, all 4 cases had close contact in a business seminar with an apparently asymptomatic Chinese woman on January 21 (who previously had contact with relatives from Wuhan); the woman states symptom onset was on a flight to Shanghai on January 23, and she was later confirmed to have 2019-nCoV. Incubation periods in these cases have been as short as 3 days. In light of the secondary cases in Germany in a business setting, the most cautious approach of having arrivals stay at home or in a hotel for 14 days after their last possible exposure in China is increasingly justified.

Updated travel advisories include: 1) Australia: reconsider travel to China; 2) Canada: avoid all travel to Hubei Province; 3) Finland: avoid nonessential travel to Hubei Province; 4) France: avoid all travel to Hubei Province; 5) Germany: avoid nonessential travel to China and avoid all travel to Hubei Province; 6) India: avoid all nonessential travel to China; 7) New Zealand: avoid all travel to Hubei Province; 8) Taiwan: avoid all nonessential travel to China.

Singapore now denies entry to residents of Hubei Province and those who have traveled there in the past 14 days.

Mongolia and 3 regions (Amur Oblast, Khabarovsk Krai, Jewish Autonomous Oblast) in Far Eastern Federal District, Russia have closed their land borders with China.

Bangladesh, Canada, India, Kazakhstan, Russia, and South Korea are arranging flights to repatriate their respective citizens from Wuhan. These persons will be closely monitored and present little threat of onward transmission.

All tourist attractions in Tibet Autonomous Region have been closed.

Current influenza vaccination is recommended to decrease the risk of simple influenza being mistaken for 2019-nCoV upon return.

Infection control supplies have been depleted in medical facilities in the smaller cities in central China; the situation is critical in many areas and resupply is uncertain.

Overall Risk Assessment

The epidemic in China is months from peaking. A report indicates that just prior to the cordoning off of Wuhan, over 5 million residents (many potentially infectious) left for other parts of China, and many thousands left for Hong Kong, Singapore, Thailand, and Japan. Exported cases have so far been to countries likely to be capable of controlling (but not preventing) ongoing transmission, which will inevitably occur. In light of the secondary cases in Germany in a business setting, the most cautious approach of having arrivals stay at home or in a hotel for 14 days after their last possible exposure in China is increasingly justified.

Based on increasing data on virology, clinical presentation, and transmission, this coronavirus closely resembles SARS-CoV in many behaviors. Fortunately, sequential sequencing of viral isolates over time indicates no significant new viral mutations; mutations often increase transmission or virulence. WHO assesses the risk of this event to be very high in China, high at the regional level, and high at the global level. The closing of Wuhan airport and the major cities of Hubei province have yet to stem the flow of exported cases. The originally implicated animal market, now closed indefinitely, bears little relevance to the ongoing situation. Whether the market was the focus of a species jump from animals to humans or merely one of multiple amplification settings for initial cases is increasingly unclear. The degree of human-to-human spread outside of Hubei province remains unclear. A reproductive number, R_0 , is estimated at 1.4–2.5 by Chinese authorities and up to 5.5 by other scientists. An R_0 greater than 1 indicates that each case leads to more than 1 subsequent case, making control much more difficult. The spectrum of disease manifestations in a large cohort study has yet to be disclosed; a severe case rate of 20% has been consistent. The existence of mildly symptomatic and asymptomatic infectious cases could increase the risk of global spread. Case fatality is impossible to ascertain at present, and lesser or greater clinical virulence compared to MERS-CoV or SARS-CoV remains speculative.

Current Disease Situation

More than 4,600 confirmed cases (976 severe and critical cases and 106 deaths) have occurred since December 8, 2019, in the provinces of Hubei (> 2,700; mainly in Wuhan), Guangdong (207), Zhejiang (173), Henan (168), Hunan (143), and Anhui (106); in the cities of Chongqing (132), Beijing (91), and Shanghai (66); and in 21 other provinces throughout the country. An additional 6,900 suspected cases have been reported since January 21, 2020. In the setting of a large outbreak and with increased delays in testing, a high proportion of suspected cases will evolve into confirmed cases. Seventy-nine cases have been discharged. Two-thirds of the cases are male. The youngest case is 10 years old and the oldest is 89; more than 70% of cases are over 40 years old, but the co-morbidity profiles of most cases are unknown.

The number of persons becoming infected with the virus has been doubling every six days. The outbreak in China is not approaching peak, and modeling indicates that is months away.

Exported Cases

Seventy-seven imported cases of 2019-nCoV (confirmed after arrival) presented at international ports of entry January 6-25 in 16 countries. Of these cases, more than 25 cases arrived in the past 7 days.

All 77 cases had exposure in Wuhan or exposure to ill persons from Wuhan in China and symptom onset dates after December 31, 2019; none had visited the implicated market.

Australia (5 cases): One case traveled while asymptomatic aboard China Southern Airlines flight CZ231 to Melbourne, Victoria State on January 19 and was hospitalized on January 23. Contact tracing is underway; movement around Melbourne was limited prior to isolation. The remaining 4 cases traveled while asymptomatic aboard flights to Sydney, New South Wales State on January 6, 18, 20, and 23, and were hospitalized on January 15, 20, and 24. One of the patients had limited movement around Sydney prior to isolation; movement history for the other 3 cases is unknown.

Cambodia (1 case): The case traveled while asymptomatic to the city of Sihanoukville on January 23, 2020, and developed symptoms on January 25.

Canada (2 cases): Both cases (a couple) traveled aboard China Southern Airlines flight CZ311 to Toronto, Ontario Province on January 22. The first case was symptomatic while traveling and was hospitalized on January 23. The second case was under self-isolation and was confirmed on January 27. Contact tracing is underway; patient movement around Toronto was limited prior to isolation.

France (4 cases): Two cases traveled while asymptomatic aboard a flight to Paris on January 18, and 1 case traveled aboard a flight to Bordeaux on January 22. Travel history for the fourth case is unknown. All cases were hospitalized.

Hong Kong (8 cases): Three cases traveled while symptomatic on January 19 and 25; the first aboard a train to West Kowloon, the second aboard a flight to Hong Kong International Airport, and the third to Lo Wu Control Point. Four of the cases traveled while asymptomatic aboard trains on January 19 and 22. The last case traveled with diminished symptoms aboard a train on January 23. All cases were hospitalized.

Japan (6 cases): Two cases traveled while symptomatic; the first aboard a flight to Kanagawa Prefecture on January 6 and the second aboard a flight to Tokyo on January 19. The first was hospitalized on January 10 and discharged on January 15 following recovery, and the second was hospitalized on January 22. Another 2 cases traveled while asymptomatic: the first aboard a flight to Tokyo on January 18 and the second aboard a flight to Aichi Prefecture on January 22. The first was hospitalized on January 23, and the second was hospitalized on January 24. The remaining 2 cases arrived on January 20 and 21 in Aichi and Tokyo prefectures.

Macau (7 cases): The first case traveled while asymptomatic aboard a train and a bus on January 19, and the second case traveled while symptomatic (travel method unknown) on January 22. The first case was hospitalized on January 19 and the second

case on January 21. The third case traveled aboard a ferry on January 23 and was immediately hospitalized. Three cases traveled (methods unknown) on January 22; all were hospitalized. The last case traveled while asymptomatic on January 23 and was hospitalized January 27.

Malaysia (4 cases): The first case traveled while asymptomatic aboard a bus to Johor Baharu on January 22 and was hospitalized on January 23. The remaining 3 cases traveled (method unknown) to Johor Baharu on January 23; all were hospitalized.

Nepal (1 case): The case traveled to Kathmandu on January 5, was hospitalized on January 13, and was discharged on January 17 following recovery.

Singapore (7 cases): All 7 cases traveled while asymptomatic aboard flights on January 18, 19, 20, 21, 22, and 23.

South Korea (4 cases): Two cases traveled while symptomatic to Incheon International Airport and to Gimpo International Airport on January 19 and 23, and both were immediately hospitalized. The remaining cases traveled while asymptomatic on January 20 and were hospitalized on January 25.

Sri Lanka (1 case): The case traveled while asymptomatic on January 29, 2020, and developed symptoms on January 25.

Taiwan (7 cases): The cases arrived on January 20, 21, 22, and 25; at least 3 cases arrived at Taiwan Taoyuan International Airport.

Thailand (14 cases): Three cases traveled while symptomatic to Suvarnabhumi Airport on January 8, 13, and 19 and were hospitalized; the travel history of the fourth case is unknown. The fifth case traveled to Bangkok on January 21 and was hospitalized on January 23. The travel histories of the remaining 9 cases are unknown.

U.S. (5 cases): Two cases traveled while asymptomatic: the first to O'Hare International Airport on January 13 and the second to Seattle-Tacoma International Airport on January 15. The first was hospitalized several days after arrival, and the second was hospitalized on January 19. The remaining 3 cases were reported in Maricopa County, Arizona and Los Angeles and Orange counties, California; information on the patients' travel histories are unknown. Contact tracing for all cases is underway. The first case reported limited movement around Chicago prior to hospitalization; movement history for the other 2 cases is unknown.

Vietnam (1 case): The case arrived in Hanoi on January 13 and was hospitalized on January 22 in Ho Chi Minh City.

In addition to these exported cases, 7 locally acquired cases have been reported since Monday in Germany (4), Japan, Taiwan, and Vietnam. The cases in Japan, Taiwan, and Vietnam reported contact with an obviously ill person from China. In Germany, all 4 cases had close contact in a business seminar with an apparently asymptomatic Chinese woman on January 21 (who previously had contact with relatives from Wuhan); the woman states symptom onset was on a flight to Shanghai on January 23, and she was later confirmed to have 2019-nCoV. Incubation periods in these cases have been as short as 3 days.

Entry/Exit Screening

In a reversal of long-standing policy, WHO now recommends that all countries implement temperature screening at points of entry for passengers arriving from 2019-nCoV-affected countries. Screening should be accompanied by dissemination of risk-communication messages at points of entry to later capture asymptomatic persons who are in the incubation phase.

In early January, some exit screening was implemented at Wuhan Tianhe International Airport (nonstop flights to Istanbul, London, New York, Osaka, Paris, Rome, San Francisco, Tokyo, and major hubs throughout Southeast Asia), as well as at 3 major rail stations in Wuhan. More restrictive screening was instituted on January 15 in Hubei until cessation of international flights on January 23. Despite exit screening at all international airports in China in the past week, significant numbers of cases continue to be exported.

Entry screening at international ports of entry has been or is being implemented as noted below, and anyone with fever and respiratory symptoms who has been to 2019-nCoV-affected areas in the previous 14 days will be detained and isolated at these locations:

Algeria: Houari Boumediene Airport, Mohamed Boudiaf International Airport, Oran Ahmed Ben Balla Airport

Burma (Myanmar): Yangon International Airport

Egypt: Cairo International Airport (all flights from China)

Hong Kong: All border checkpoints, including Hong Kong International Airport and the railway station in West Kowloon

India: Bengaluru, Chennai, Delhi, Hyderabad, Kochi, Kolkata, and Mumbai international airports (all flights from China and Hong Kong)

Italy: Leonardo da Vinci-Fiumicino Airport

Iran: Tehran Imam Khomeini International Airport (all flights from China)

Macau: Macau International Airport

North Macedonia: Skopje International Airport (connecting flights from Asia)

Qatar: Hamad International Airport (all flights from China)

Russia: Moscow, Irkutsk Oblast, and Yekaterinburg international airports and points of entry in Amur Oblast

Singapore: Changi Airport

South Africa: O.R. Tambo International Airport (all flights from China)

South Korea: Incheon International Airport

Taiwan: All international airports

Thailand: Krabi, Suvarnabhumi, Don Mueang, Phuket, and Chiang Mai airports

Turkey: All international airports (all flights from China)

United Arab Emirates: Abu Dhabi International Airport and Dubai International Airport (all flights from China)

U.K.: Heathrow International Airport

U.S.: Twenty points of entry, including Hartsfield-Jackson Atlanta International Airport, John F. Kennedy International Airport, Los Angeles International Airport, O'Hare International Airport, and San Francisco International Airport. Travelers from Wuhan may have their temperatures taken and/or be required to complete a symptom questionnaire; travelers with symptoms (fever, cough, difficulty breathing) will be detained for additional assessment.

Australia, Bahrain, Bangladesh, Belarus, Canada, Cote d'Ivoire, Ghana, Indonesia, Japan, Kazakhstan, Kenya, Kyrgyzstan, Madagascar, Malaysia, Nepal, Nigeria, North Korea, Philippines, Saudi Arabia, Serbia, Senegal, Sri Lanka, Tajikistan, Tunisia, Vietnam: Airports and other ports of entry

Travel Advisories

The following countries and/or organizations have published travel recommendations:

Avoid All Travel to Hubei Province: Australia, Canada, China (see below), France, Germany, Japan, Mexico, New Zealand, U.K., U.S.

Avoid Nonessential Travel to Hubei Province: Finland, Ukraine

Avoid All Travel to China: None at present

Avoid Nonessential Travel to China: Australia, Germany, India, Taiwan, U.S.

No Advisory: WHO

Travel Restrictions

Different levels of travel restrictions are in effect:

No Flights from China: Finnair Airlines (flights from Beijing and Nanjing), Air Seoul

No Flights from Wuhan: Wuhan Airport is closed to all international and domestic flights.

Land Borders with China Closed: Kyrgyzstan, Mongolia, North Korea, Russia (Amur Oblast, Khabarovsk Krai, Jewish Autonomous Oblast in Far Eastern Federal District); high speed rails and ferry services suspended in Hong Kong

No Residents from Hubei Province: Hong Kong, Macau, and Singapore (including visitors in past 14 days), Malaysia, and Taiwan

Internal Travel Restrictions in China: Major cities in Hubei Province have instituted a travel ban on occupants of their cities, suspending urban buses, subways, ferries, and long-distance passenger transport from the cities, including flights and trains, and closing intercity roads. Interprovince shuttle buses in major areas have stopped. Many bars, restaurants, shops, and museums are closed in Hubei Province, Guangdong, and many other affected areas. Major tourist attractions have closed in Beijing, Shanghai, Sanya (Hainan Province), Hong Kong, and Tibet Autonomous Region. China has stopped all inbound and outbound tour groups but not individual travel. Internal travel for the Lunar New Year Holiday has been severely limited by the government, and public gatherings are forbidden. The reopening of schools and universities has been postponed in many areas. Shanghai has temporarily closed all nonessential workplaces. Visitors from Hubei Province will be actively monitored for 14 days in Haikou, Hainan Province.

No Flights from 2019-nCoV–Affected Countries: Travelers going to Samoa must spend at least 14 days in a country free of 2019-nCoV and undergo medical clearance prior to travel to Samoa.

Australia, Bangladesh, Belgium, Canada, France, Germany, India, Japan, Kazakhstan, Morocco, Netherlands, Russia, South Korea, Spain, Thailand, U.K., and U.S. are arranging flights to repatriate their respective citizens from Wuhan. These persons will be closely monitored and present little threat of onward transmission.

Transmission

The detailed epidemiology of possible causative animal exposures and zoonotic transmission remains unclear. Many (27 of 41) earlier cases were directly linked to South China Seafood City market in Jiangnan District, which sold seafood and other wildlife (including birds). More than 580 environmental samples, without indication as to whether animal tissue was included, were collected from the implicated market. Of these, 33 tested positive for 2019-nCoV, indicating that the market was an—or the—origin point of the large-scale outbreak. Thirty-one of the positive samples (94%) were collected from the western part of the market, where wildlife was traded. The first published epi-curve shows that the symptom onset date of the first patient identified in the outbreak was December 1, 2019. The patient reported no exposure to the implicated market; no epidemiological link has been detected between this case and later cases. This finding raises the possibility of an initial jump of 2019-nCoV directly from bat to human, with subsequent initial human-to-human propagation within the seafood market.

Infected intermediate animal hosts, if they exist, may still be present in the supply chain. South China Seafood City market, now closed indefinitely, remained in operation through December 31, 2019. Other points of infection would be likely because many subsequent cases had no contact with the implicated market. Chinese authorities have now stated that human-to-human transmission is in the fourth generation in Wuhan and at least the second generation elsewhere (mostly in clusters). A reproductive number, R_0 , is estimated at 1.4–2.5 by Chinese authorities and at up to 5.5 by some scientists. An R_0 greater than 1 indicates that each case leads to more than 1 subsequent case, making control much more difficult. R_0 is not a constant number and changes with the ongoing circumstances and evolution of an outbreak. One published cluster study indicates asymptomatic shedding (but not transmission) by a single patient. Sequence data from several small clusters indicate identical virus in all subjects within the cluster.

More than 47,800 close contacts remain under surveillance (> 1,200 have been released), and contact tracing is ongoing in affected provinces and municipalities. However, not all contacts are being ascertained or monitored adequately. As many as 16 health care workers (HCWs) have been confirmed as infected by at least 1 case in Wuhan in a potential super-spreading event, but overall infectivity for HCWs has not been established. No case of 2019-nCoV has been attributed to transmission on an aircraft.

The survival rate of the virus on surfaces or in the environment is unknown. Disinfection processes that are effective for other zoonotic coronaviruses should be followed for now. Clean daily all "high-touch" surfaces, such as counters, tabletops, doorknobs, bathroom fixtures, toilets, phones, keyboards, tables, and bedside tables. Also, clean any surfaces that may have blood, bodily fluids, and/or secretions or excretions on them. Use a diluted bleach solution or a household disinfectant with a label that says "EPA-approved." To make a bleach solution, add 15 mL (1 tablespoon) of bleach to 1 L (1 quart) of water; for a larger supply, add 60 mL (2 oz) of bleach to 4 L (1 gallon) of water.

Clinical Manifestations

Most cases have reportedly exhibited symptoms of fever, respiratory compromise, and bilateral pneumonia with diffuse, ground glass-like infiltrates on chest x-ray or CT scan. Unlike SARS-CoV, upper respiratory illness symptoms (rhinorrhea, sneezing, sore throat) and diarrhea are not common. Overall, about 20% of the cases have been severe or critical, including pneumonia, respiratory failure, and in some cases death. The existence of asymptomatic cases has not been ascertained. No known treatment exists for 2019-nCoV, although remdesivir will be available shortly from the U.S. CDC for compassionate use. Usual antiviral drugs, including oseltamivir (Tamiflu), baloxavir, ribavirin, and acyclovir, are ineffective. Steroids should not be used. Based on earlier literature, the combined use of lopinavir and ritonavir is under study in China. Current influenza vaccination is recommended to decrease the risk of simple influenza being mistaken for 2019-nCoV upon return.

In a small cohort of 41 patients (median age was 49 years; interquartile range: 41-58) conducted early in the epidemic (presentation before January 2), the most common symptoms at onset of illness were fever (98%), cough (76%), and myalgia or fatigue (44%). Dyspnea developed in 55% of patients at a median of 8 days. All cases except 1 had bilateral pneumonia. Milder cases had chest CTs that showed bilateral ground-glass opacity with subsegmental areas of consolidation, whereas ICU patients had bilateral lobar and subsegmental areas of consolidation. Only 66% of cases (even in this early cohort) had been exposed to the South China Seafood City market. The case-fatality rate was estimated to be 15%, but more severe cases tend to predominate early in an epidemic. Limited data from another published cluster study indicate a 3- to 6-day incubation period similar to SARS-CoV and clinical and radiologic features similar to SARS-CoV cases in 2003. Another report indicates an incubation period ranging from 1 to 14 days.

Virology

2019-nCoV was initially isolated from 1 case and entirely sequenced; this information was published internationally by Chinese scientists on January 10. Electron microscopy of 1 specimen demonstrated classic coronavirus particles. 2019-nCoV is the seventh

member of the family of coronaviruses that infect humans. Novel coronaviruses from Wuhan, together with 2 bat-derived SARS-like strains, form a distinct clade in lineage B of the subgenus sarbecovirus. 2019-nCoV is a group 2b coronavirus (as are MERS-CoV and SARS-CoV), with a whole genome similarity of up to 80% to SARS-CoV but with a similarity between different gene segments ranging from 60% to 90%. 2019-nCoV exhibits a 96.5% similarity to the known bat coronavirus precursors in the same viral clade.

Sequence data allowed national laboratories to rapidly develop diagnostic kits, which are now available in most developed countries and most Asian countries. HKU1, NL63, 229E, and OC43 are human coronaviruses that are detected by some routine multiplex PCR panels used in routine clinical practice. These coronaviruses are associated with minor upper respiratory infections and viral pneumonia, but unlike SARS-CoV, MERS-CoV, and 2019-nCoV, these agents are not associated with major outbreaks or severe respiratory distress syndrome. 2019-nCoV is not reactive in these tests. The findings so far strongly favor (but do not prove) causation. 2019-nCoV has been shown to use the same cell-entry receptor as SARS-CoV. Viral loads appear to be highest in lower respiratory tract specimens, which should be the primary specimen obtained. Prediction of human-to-human transmissibility from sequence data is difficult because coronaviruses vary widely in their transmissibility; coronaviruses acquired from animals generally have some potential for human-to-human transmission. Evidence from subsequent whole genome sequences acquired over the last several weeks show little genetic variation, indicating that the virus jumped from an animal reservoir to humans within the last few months. Identical recent mutations in epidemiologically unlinked cases support sustained human-to-human transmission.

Criteria for Testing of Suspected Cases

U.S. CDC

Persons meeting the following criteria (clinical features and epidemiologic risk) for suspected cases of 2019-nCoV will be considered persons under investigation (PUI):

- Fever *and* symptoms of lower respiratory illness (e.g., cough, shortness of breath) *plus* a history of travel to Wuhan or close contact with a PUI for 2019-nCoV while that person was ill in the past 14 days before symptom onset
- Fever *or* symptoms of lower respiratory illness (e.g., cough, shortness of breath) *plus* close contact with an ill, laboratory-confirmed 2019-nCoV case in the past 14 days before symptom onset

HCWs entering the room with a PUI should use standard precautions, contact precautions, airborne precautions, and eye protection (e.g., goggles or a face shield).

PUIs for 2019-nCoV should be asked to wear a surgical mask as soon as they are identified and be evaluated in a private room with the door closed, ideally an airborne-infection isolation room if available.

Prevention

Travelers going to Wuhan should avoid animals (alive or dead), animal markets, products that come from animals (such as uncooked meat), and contact with ill-appearing persons. Quality of infection control at medical facilities in Wuhan is uncertain, and those with minor medical problems should avoid busy medical settings.

Infection control supplies have been depleted in medical facilities in the smaller cities in central China; the situation is critical in many areas and resupply is uncertain. Travelers who develop fever and respiratory symptoms within 14 days of travel to Wuhan should immediately be isolated, and public health authorities should be alerted.

Employees, Students, Visitors, All Others Coming from Wuhan

Whether asymptomatic individuals infected with 2019-nCoV are infectious to others is unknown. Influenza viruses can be transmitted 1 to 2 days prior to symptom onset. SARS-CoV did not transmit until 4 days after symptom onset, which led to its eradication because all contacts with fever could be promptly identified and isolated.

If 2019-nCoV is similar to SARS-CoV, asymptomatic arrivals from Wuhan should self-monitor by taking a temperature reading immediately prior to coming into the workplace or school for 14 days after their last exposure in Wuhan. Arrivals with fever at any time should self-report to public health authorities (or telephone ahead before presenting to a hospital) and should wear a mask as soon as possible. A more stringent approach would require that an employee, student, or visitor—upon arrival to a workplace or school—be instructed to perform an additional temperature check in the presence of medical personnel to ensure compliance with local self-monitoring requirements. In addition, prior to any gathering of ≥ 2 persons, attendees could be required to perform additional self-monitoring.

Based on advanced information and employee or visitor medical screening, additional preventive measures may be required (e.g., increased ventilation, larger meeting rooms with more personal space per participant, disinfection of work areas and lavatories, and provision of alcohol wipes).

The most cautious approach would be for arrivals to stay at home or in a hotel for 14 days after their last possible exposure in China. To date, all known cases exported to other countries had either visited Wuhan or had contact with an ill person from Wuhan while in China.

Sent from my magical iPad!

On Jan 29, 2020, at 2:46 PM, Richard Tubb <bg.richard.tubb@gmail.com> wrote:

—
Richard J. Tubb, MD
Brigadier General (retired)
White House Physician Emeritus

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 04:03:31 +0000
To: Howard Bauchner
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Study+claiming+new+coronavirus+can+be+transmitted+by+people+without+symptoms+was+flawed

Thanks, Howard. Talk soon.

-----Original Message-----

From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Sent: Wednesday, February 5, 2020 6:37 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: RE: Study+claiming+new+coronavirus+can+be+transmitted+by+people+without+symptoms+was+flawed

The author of our case-series - proof today will send to you - is an ICU doc in Wuhan - trained with Derek Angus - he has been great - but I have asked him about himself, his family - we loss track of the personal - which is so important.

I have had a few "emergencies" like this - at BCH - with Jerry Klein - some infectious disease outbreaks; a couple major car accidents; etc. Also worked at the Berhorst Clinic in Guatemala in 1978 (before there was global health) numerous 5-10-15 people emergencies - always end though - for you this is the pandemic that never stops giving.

Try to take a break; have a good glass of Claret on me.

HCB

-----Original Message-----

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Sent: Wednesday, February 05, 2020 5:31 AM
To: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: RE: Study+claiming+new+coronavirus+can+be+transmitted+by+people+without+symptoms+was+flawed

[Warning External Email]

Howard:

Your outline looks fine. Am hanging in there. Feels like my internship and first year residency when I was on every other night and every other weekend, but actually never left the hospital because the patients were so sick.

Best,
Tony

-----Original Message-----

From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Sent: Wednesday, February 5, 2020 6:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: RE: Study+claiming+new+coronavirus+can+be+transmitted+by+people+without+symptoms+was+flawed

Likely come up tomorrow in our discussion - not NEJM paper but just the concept.

Outline if OK with you

What's up in China

What's up around the world

What's up in US

And then more specific questions

Is this more like H1N1 than MERS

Can we really know mortality risk (denominator problem).

Incubation period

How "infectious"

News on treatment

Quarantine working

Sound OK?

You surviving - worried a bit about your workload.

HCB

-----Original Message-----

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Sent: Wednesday, February 05, 2020 5:20 AM

To: Howard Bauchner <Howard.Bauchner@jamanetwork.org>

Subject: RE: Study+claiming+new+coronavirus+can+be+transmitted+by+people+without+symptoms+was+flawed

[Warning External Email]

The paper was flawed. Embarrassment for NEJM. However, the concept is correct. Spoke in detail to the Director of the Chinese CDC (confidential) and they are seeing asymptomatic transmission (low level) in China.

-----Original Message-----

From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>

Sent: Wednesday, February 5, 2020 6:15 AM

To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>

Subject: FW: Study+claiming+new+coronavirus+can+be+transmitted+by+people+without+symptoms+was+flawed

Tony

Support you saw this. Big problem if true - rushing to publication - leads to big mistakes.

HCB

-----Original Message-----

From: Redberg, Rita <(b) (6)>

Sent: Wednesday, February 05, 2020 5:13 AM

To: Howard Bauchner <Howard.Bauchner@jamanetwork.org>; Phil Fontanarosa
<Phil.Fontanarosa@jamanetwork.org>
Subject: Study+claiming+new+coronavirus+can+be+transmitted+by+people+without+symptoms+was+flawed

[Warning External Email]

Assume you saw, but.

https://urldefense.proofpoint.com/v2/url?u=https-3A__www.sciencemag.org_news_2020_02_paper-2Dnon-2Dsymptomatic-2Dpatient-2Dtransmitting-2Dcoronavirus-2Dwrong&d=DwIFAg&c=iqeSLYkBTkTEV8nJYtdW_A&r=CpYvDJwppPNcFUZ7y8a6zr8BltWA4gtfRWytiKffoVM&m=4xruNHFPsXovMmiMLZW-iD9OzCNhiiGOKmtHhrZcP8c&s=afNfNjVB5xiV3y8BiCPHkwBnAiRXsktAbHlrM9a3jPY&e=

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 03:59:46 +0000
To: Auchincloss, Hugh (NIH/NIAID) [C] (b) (6)
Subject: FW: touching base about Texas Biomedical Research Institute

Please take care of this .

From: Larry Schlesinger (b) (6)
Sent: Wednesday, February 5, 2020 8:42 AM
To: Auchincloss, Hugh (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: touching base about Texas Biomedical Research Institute

Hi Tony and Hugh.

I know that I am writing to you at a busy time during yet another infectious disease outbreak that is rapidly evolving. However, I wanted to send you a brief note to update you about the transformational change going on in the landscape of our free standing institute with its new, sharply defined goal to be the global leader in eradicating infectious disease threats in the world. I know that you are familiar with us.

I have been leading the institute since June of 2017 and currently finishing year one of a 10 year board-approved plan of growth in our scientists, educational programming and campus modernization. I believe that you are aware that we house the only private BSL4. We also just opened our newest of 5 BSL3 facilities, this newest one being nearly 8000 sq. ft. with capacity for ~100 NHPs, small animals, a complete aerosol suite and a PET CT. We also house the SNPRC, now under the leadership of Deepak Kaushal (who replaced Robert Lanford) and with the largest marmoset colony as a result of restructuring our building facilities (in addition to our other species). (b) (4)

Please check out our newly designed website: www.txbiomed.org.

The bottom line is that I left university life to lead an organization that is determined to not only discover critical, new fundamental science but also effectively and efficiently bring it full forward to create portfolios for the FDA through our business model, nimbleness, regulated science culture (GLP level), longstanding public and private partners through contract science (esp. BARDA), culture and community support.

We want to help! Please let us know if and how we can contribute to this outbreak and undoubtedly others going forward.

I truly appreciate your leadership. The country gets the voice of reason on infectious disease outbreaks through your public efforts. I enjoyed learning more about this during my time on council.

Best,

Larry

Larry Schlesinger, MD
Professor
President and CEO
Texas Biomedical Research Institute
8715 W. Military Drive, San Antonio, TX 78227
Email: (b) (6)
Teamwork | Integrity | Diversity | Excellence | Safety

Executive assistant:

(b) (6)
(b) (6) Phone
(b) (6) Mobile
Email: (b) (6)

CONFIDENTIALITY NOTICE: This e-mail and any files and/or attachments transmitted, may contain privileged and confidential information and is intended solely for the exclusive use of the individual or entity to whom it is addressed. If you are not the intended recipient, you are hereby notified that any review, dissemination, distribution or copying of this e-mail and/or attachments is strictly prohibited. If you have received this e-mail in error, please immediately notify the sender stating that this transmission was misdirected; return the e-mail to sender; destroy all paper copies and delete all electronic copies from your system without disclosing its contents.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 03:49:36 +0000
To: Robert Knobler
Cc: Casetti, Cristina (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Potential Approach to Wuhan Coronavirus

Bob:

Thanks for your note. It was good to hear from you. I am copying Cristina Casetti on this e-mail. Cristina directs the extramural coronavirus research activities. Perhaps you two can connect to discuss research opportunities.

Best,

Tony

-----Original Message-----

From: Robert Knobler [REDACTED] (b) (6)
Sent: Wednesday, February 5, 2020 10:55 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6)>
Subject: Potential Approach to Wuhan Coronavirus

Dear Dr. Fauci,

You likely do not recall meeting me when I was looking at potential fellowships in 1978, however, I never forgot your enthusiasm. I went out to San Diego and worked with Mike Oldstone, between 1979 and 1984.

I did study a mouse coronavirus while there, mouse hepatitis virus (MHV). I focused on genetic resistance, and eventually described a mouse locus for susceptibility, which coded for the MHV receptor.

Lacking the correct receptor or blocking binding of the virus spike protein to the receptor with monoclonal antibodies blocked infection.

On to the present problem of human coronaviruses. Vaccines will take a long time for the current crisis. The angiotensin converting enzyme 2 receptor has been identified as the relevant human coronavirus receptor in earlier studies of SARS and MERS human coronavirus outbreaks. I am writing to suggest the investigation of ARBs as potential blocking agents to either reduce or completely block infection. Perhaps this can be checked. If correct, there may still be sufficient untainted supplies of ARBs, such as irbesartan, available, or production can be scaled up, if this truly is the eve of a pandemic.

Wishing you success in this endeavor. I am willing to contribute in any way I can. Please feel free to contact me by e-mail or my cell phone.

I also did do clinical trials while with Mike, and then when I joined the neurology faculty of Jefferson in Philadelphia. I have been out on my own since December 1998, but I have never lost my interest in this work. For another time, I also have some novel ideas on how HIV becomes AIDS, as well. Ironically, these ideas were based upon observations I made during my analysis of MHV.

All the Best,

Robert L Knobler, MD, PhD

[REDACTED] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 03:28:54 +0000
To: Cohen, Elizabeth
Subject: RE: treatment protocols

The Chinese are putting together protocols to test certain drugs such as remdesivir.

From: Cohen, Elizabeth <Elizabeth.Cohen@turner.com>
Sent: Wednesday, February 5, 2020 3:19 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: treatment protocols

Hi Tony,

We were wondering if there are any particular protocols being suggested for treating the Wuhan coronavirus cases in the US. Are there discussions among the teams caring for these patients about the best approach?

Many thanks.

Best,
Elizabeth

Elizabeth Cohen, MPH
CNN Senior Medical Correspondent

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 02:54:42 +0000
To: Casetti, Cristina (NIH/NIAID) [E]
Subject: FW: Corona virus/sepsis treatment
Attachments: CBR Baum Satz (5).pdf, Kim Brechbiel Satz.pdf, Kim supplement-01.doc, REFERENCES Corona Virus.docx

Please handle.

From: stanley satz [REDACTED] (b) (6)
Sent: Wednesday, February 5, 2020 7:20 PM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Corona virus/sepsis treatment

Dear Dr. Fauci,



(b) (4)

Best regards,

Stanley Satz, Ph.D.
Chairman and Chief Scientific Officer

Advanced Innovative Partners, Inc.

Professor, Florida Atlantic University,
University of Miami School of Medicine

www.advancedinnovativepartners.com
www.bionucleonics.com

(b) (6)

--

Confidentiality Notice

This message is being sent by or on behalf of Dr. Satz. It is intended exclusively for the individual or entity to which it is addressed. This communication may contain information that is proprietary, privileged or confidential or otherwise legally exempt from disclosure. If you are not the named addressee, you are not authorized to read, print, retain, copy or disseminate this message or any part of it. If you have received this message in error, please notify the sender immediately by e-mail and delete all copies of the message.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 02:54:19 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Haskins, Melinda (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Dr. Levitt summarizes CDC 2019-nCoV Committee Report released today 5 Feb 2020
Attachments: M and M Wuhan Virus.pdf

See me about getting someone to prepare a response.

From: Robert Levitt (b) (6) >
Sent: Wednesday, February 5, 2020 7:50 PM
To: Azar, Alex (OS/IOS) (b) (6) >; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Dr. Levitt summarizes CDC 2019-nCoV Committee Report released today 5 Feb 2020

Dear Secretary Azar and Dr. Fauci,

I have read carefully the CDC's report issued this morning on the Wuhan virus (2019-nCoV) epidemic originating in Wuhan, Hubei Province, PRC. The Report was prepared by CDC's best Ph.D.s, M.D.s, and D.V.M.s. See the pdf attached above for the complete report.

Below I have recorded what I think the most important facts in the report for Secretary Azar and other federal officials who must stop the spread of 2019-nCoV in the U.S. by identifying all infected persons and their contacts. I have also added my personal thoughts on how to stop the spread of this novel coronavirus and a personal fear I have communicated to Secretary Azar in the past:

-- President Trump signed an order preventing entry into the U.S. of any person who has traveled to mainland China (PRC). Exceptions include U.S. citizens and permanent residents and their families. Thank you Mr. Trump.

-- CDC maintains an office in the PRC. So information from Wuhan, Hubei, PRC, should be 'real time'.

-- Enhanced screening of persons entering the U.S. is taking place at 18 ports and 5 airports. The number of ports and especially airports needs to be increased. The Report states that 14,000 Chinese enter the U.S. daily. **If the 5 airports receive 85% of these Chinese, then 2,100 Chinese enter the U.S. daily at other airports without enhanced screening.**

-- CDC has developed its own RT-PCR test to detect 2019-nCoV in respiratory specimens. I have read case reports where state laboratories have required too much proof of suspected Wuhan virus from clinicians before performing RT-PCR testing of specimens. **CDC should provide their improved RT-PCR test to all states and HHS should insure that all states have sufficient equipment and trained personnel for rapid turn-around time.**

- CDC has grown the 2019-nCoV virus. **CDC should expedite distribution of the grown virus to researchers with verified credentials and vetting in a safe and monitored procedure.**
- CDC recommends that persons suspected by clinicians of having 2019-nCoV be placed in a separate room with a N95 face mask so that they are not in range of other patients. **HCW should wear personal protection: gloves, gown, face shield or N95 mask and goggles.**
- Clinicians have identified 8 of the current 11 patients infected with 2019-nCoV in the U.S. **CDC is doing a terrific job in getting the message out to clinicians and the public.**

Sent from [Outlook](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 00:56:18 +0000
To: Mak, Tak
Cc: Cassetti, Cristina (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: An Idea

Tak:

Thanks for the note. It likely will be more efficient if I refer you to the program people in my Institute who could go over these data with you and then get me involved later. The reason that is that I am doing 18 hours pe day (seriously) as part of the White House Task Force and it would very difficult for me to fit in a meeting to go over data. I have copied Dr. Cristina Cassetti who runs our coronavirus extramural research program. I will ask her by this e-mail to contact you to have our people discuss your work with you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mak, Tak <(b) (6)>
Sent: Wednesday, February 5, 2020 7:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: An Idea

Dear Tony,

It has been a while since we discussed science. (b) (4)

(b) (4)

Best regards, Tak

This e-mail may contain confidential and/or privileged information for the sole use of the intended recipient.

Any review or distribution by anyone other than the person for whom it was originally intended is strictly prohibited.

If you have received this e-mail in error, please contact the sender and delete all copies.

Opinions, conclusions or other information contained in this e-mail may not be that of the organization.

If you feel you have received an email from UHN of a commercial nature and would like to be removed from the sender's mailing list please do one of the following:

(1) Follow any unsubscribe process the sender has included in their email

(2) Where no unsubscribe process has been included, reply to the sender and type "unsubscribe" in the subject line. If you require additional information please go to our UHN Newsletters and Mailing Lists page.

Please note that we are unable to automatically unsubscribe individuals from all UHN mailing lists.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 00:00:36 +0000
To: Jeremy Farrar;Collins, Francis (NIH/OD) [E]
Cc: Josie Golding;Tabak, Lawrence (NIH/OD) [E]
Subject: RE: Prevalence of infection and stage of the epidemic in Wuhan

Jeremy:

I left out an important name for the coronavirus evolution working group. Please include her: Pardis Sabeti at the Broad Institute of MIT and Harvard

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wednesday, February 5, 2020 5:25 PM
To: Jeremy Farrar <(b) (6)>; Collins, Francis (NIH/OD) [E] (b) (6)
Cc: Josie Golding <(b) (6)>; Tabak, Lawrence (NIH/OD) [E] (b) (6)
Subject: RE: Prevalence of infection and stage of the epidemic in Wuhan

Jeremy:

Thanks for the note. Looks like things are moving along with WHO. I will list below a number of names for potential members of the working group to examine the evolutionary origin of the 2019-nCoV in addition to the individuals who were on the call with us last Saturday:

Harold Varmus – Weill Cornell Medical Center – New York City

Feng Zhang – MIT (CRISPR expert)

Joseph DeRisi - Chan Zuckerberg (CZ) BioHub (he's paying close attention to the Wuhan strain vs other bat viruses and the SARS virus)

Don Ganem - University of California at San Francisco (UCSF) and the CZ BioHub (knows more about hepadnaviruses but an outstanding clinical and basic virologist)

John Coffin - Tufts and National Cancer Institute, NIH (worked out the confusion over the alleged Chronic Fatigue Syndrome retrovirus that proved to be a xenotropic MLV)

Eugene Koonin - NCBI/National Library of Medicine, NIH;

<https://www.ncbi.nlm.nih.gov/research/groups/koonin/>)

Wayne Hendrickson - Columbia University and the New York Structural Biology Center

Gary Nabel - Sanofi (Boston)

Best regards,

Tony

Anthony S. Fauci, MD

Director

National Institute of Allergy and Infectious Diseases

Building 31, Room 7A-03

31 Center Drive, MSC 2520

National Institutes of Health

Bethesda, MD 20892-2520

Phone: (b) (6)

FAX: (301) 496-4409

E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar (b) (6)

Sent: Wednesday, February 5, 2020 6:21 AM

To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Collins, Francis (NIH/OD) [E] (b) (6) >

Cc: Josie Golding (b) (6)

Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

Francis and Tony

Couple of things:

- I spoke again with WHO this morning. I believe they have listened and acted. Let me know if you agree
 - At the WHO meeting next week they will set up the Group who will "look at the origins and evolution of 2019n-CoV"
 - They have asked for names to sit on that Group – please do send any names

- We can have a call this week with a core group of that to frame the work of the Group including – if you could join?
- I think this puts it under the umbrella of WHO, with action this week and into next
- With names to be put forward into the Group from us and pressure on this group from your and our teams next week.
- The team will update the draft today and I will forward immediately – they will add further comments on the glycans

Does that sound reasonable to you?

Jeremy

From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)
Date: Tuesday, 4 February 2020 at 13:18
To: Francis Collins <(b) (6)>, Jeremy Farrar (b) (6)
Subject: RE: Prevalence of infection and stage of the epidemic in Wuhan

?? (b) (4)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] (b) (6)
Sent: Tuesday, February 4, 2020 6:12 AM
To: Jeremy Farrar (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: RE: Prevalence of infection and stage of the epidemic in Wuhan

Yes, (b) (4)

Francis

From: Jeremy Farrar [REDACTED] (b) (6)
Sent: Tuesday, February 4, 2020 6:08 AM
To: Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6) >
Cc: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >
Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

[REDACTED] (b) (4)

On 4 Feb 2020, at 10:58, Collins, Francis (NIH/OD) [E] [REDACTED] (b) (6) > wrote:

Very thoughtful analysis. [REDACTED] (b) (4)
[REDACTED] (b) (4)

Francis

From: Jeremy Farrar [REDACTED] (b) (6)
Sent: Tuesday, February 4, 2020 2:01 AM
To: Fauci, Anthony (NIH/NIAID) [E] [REDACTED] (b) (6) >; Collins, Francis (NIH/OD) [E] <[REDACTED] (b) (6)>
Subject: FW: Prevalence of infection and stage of the epidemic in Wuhan

Please treat in confidence – a very rough first draft from Eddie and team – they will send on the edited, cleaner version later.

Pushing WHO again today

From: Edward Holmes [REDACTED] (b) (6) >
Date: Tuesday, 4 February 2020 at 06:33
To: Jeremy Farrar [REDACTED] (b) (6) >
Subject: Re: Prevalence of infection and stage of the epidemic in Wuhan

Here's our summary so far. Will be edited further.

It's fundamental science and completely neutral as written. Did not mention other anomalies as this will make us look like loons. As it stands it is excellent basic science I think, which is a service in itself.

Will finish as soon as we can.

PROFESSOR EDWARD C. HOLMES FAA FRS

ARC Australian Laureate Fellow

THE UNIVERSITY OF SYDNEY

Marie Bashir Institute for Infectious Diseases & Biosecurity,
School of Life & Environmental Sciences and School of Medical Sciences,
The University of Sydney | Sydney | NSW | 2006 | Australia

T (b) (6)

E (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 5 Feb 2020 20:52:29 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: note to Patty -- and Tony Fauci

Let us discuss. Steve is a good guy, but I do not want to kill myself trying to do too many things at the same time.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6) >
Sent: Wednesday, February 5, 2020 3:27 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: note to Patty -- and Tony Fauci

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it

from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Steve Clemons <sclemons@thehill.com>

Sent: Wednesday, February 5, 2020 3:20 PM

To: Conrad, Patricia (NIH/NIAID) [E] [REDACTED] (b) (6)

Subject: note to Patty -- and Tony Fauci

Greetings Patty and Tony -- I see you on TV constantly guiding us through the terrain on our preparedness for outbreaks such as what we have seen in China. I want to see if I can add one more request to your pile to think about....and I am trying to see if what I am suggesting might work right before your Aspen talk next Tuesday at noon.

In addition to my great role at The Hill, I am host of a new show called "The Bottom Line" on Al Jazeera English that runs four times a week on their global network and is garnering between 100k-200k views a week on YouTube in the US. The show is doing really well and is a 24 minute panel discussion of three experts on a single topic that I facilitate. I would love to have you, Tony, be the anchor commentator on what we should do not only on the coronavirus but in general on the infrastructure of pandemic preparedness in the country -- sort of a shorter form of that great PBS show you did called Invisible Killers.

We would want to tape in our studio at 21st and M Streets NW from 11:00 am - 11:30 am (we don't go over), or I could move it 15 to 30 minutes earlier if you like next Tuesday, 11 February. I know you have to be at Aspen at noon (I was invited too) -- so I could take you if you like.

I realize that this may be too much . -- but in these times, I think it's important to get smart commentary and analysis out there -- and I think I can add a couple hundred thousand eyeballs and ears to the millions you are already reaching. The producers are also able to provide car and driver [REDACTED] (b) (4)

[REDACTED] (b) (4)

Hope this might work my friend. I may send a short form of this to your cell phone.

Call me if you want to chat, either of you, at [REDACTED] (b) (6).

all best, STEVE



TheHill.com

Steve Clemons

Editor at Large, The Hill

1625 K Street NW, Suite 900

Washington, DC 20006

Tel: +1.202.628.8500

Cell: [REDACTED] (b) (6)

Email: SClemons@TheHill.com

Follow me on Twitter [@SCClemons](https://twitter.com/SCClemons)

From: (b) (6)
Sent: Wed, 5 Feb 2020 10:33:15 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: NTV Broadcasting Interview Request

FYI

Begin forwarded message:

From: Сефербеков Хаджи-Мурат Караханович <HSeferbekov@ntv.ru>
Date: February 5, 2020 at 10:21:15 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6)>
Subject: NTV Broadcasting Interview Request

Mr. Fauci, my name is Murat, I am a producer of "Week Summary" for NTV Broadcasting company.

We would like to film a brief interview with you about coronavirus, and different hypotheses about its appearance. We want to solve the problem with mass disinformation about this virus, and need a professional opinion.

Will it be possible to do this at 6th, or 7th of February?

Best regards,
Seferbekov Murat
NTV Broadcasting Company

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 5 Feb 2020 14:36:13 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Interview request by BBC Chinese

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Tsung-Hsien Lee <zach.lee@bbc.co.uk>
Sent: Wednesday, February 5, 2020 8:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Interview request by BBC Chinese

Dear Dr Anthony S Fauci,

This is Zachary from BBC Chinese.

I am now writing a piece regarding the treatment of people in isolation or quarantine over coronavirus in different countries.

Most of the countries told the public where the people evacuated from Wuhan reside for quarantine and some drew local's protests. They expressed concern over close vicinity and some even went to protest in these places.

Others like Taiwan, the authority decided to keep the quarantine location confidential. The reason is to avoid unnecessary worrisome and let people rest well.

I would like to have an interview with you by e-mail or Skype phone with you to give some insights or comments on this issue.

If you could be quoted, the questions are as below

1. Why does the government tell the public the quarantine location? Is it necessary? Or why not?

2. Many residents protested because they don't want the quarantine Center for Coronavirus in their neighborhood. Do they need to worry about it?

3. What is your suggestion regarding the location of quarantine those people from Wuhan. And what is essential for Quarantine Center for Coronavirus?

Thank you very much for your time.

Zachary Lee

BBC Chinese

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 13 Feb 2020 22:36:17 +0000
To: Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Subject: RE: NAS

Nancy:

The official USG group will be convened by NAS. Bob Kadlec is the person with direct knowledge of that. In addition, there is an ad hoc group informally led by Jeremy Farrar of Wellcome Trust. This group has about 15 people, all of whom are highly respected scientists, mostly evolutionary biologists who are convening by e-mail and conference calls (I have been on 2 of these calls since Jeremy invited me) to look at all of the bat, pangolin and human coronavirus sequences to try and determine the evolutionary origin. This is not my area of expertise and so I have backed off and am leaving it all to Jeremy.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b) (6) >
Sent: Thursday, February 13, 2020 5:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: RE: NAS

Thanks. Is someone convening them?

From: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Sent: Thursday, February 13, 2020 5:07 PM

To: Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b) (6)
Subject: RE: NAS

Nancy:

It is not a report. It is a letter from NAS to OSTP saying that it is important to bring together a group of experts to study the evolutionary origin the COVID19. I am attaching it here. I have no idea if it has been widely distributed and so please keep it internal.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b) (6)
Sent: Thursday, February 13, 2020 1:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: NAS

Either you or Bob Kadlec made reference to a NAS report on the origins of SARS – COV2. (b) (5)

Thanks.
Nancy

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 13 Feb 2020 22:06:37 +0000
To: Messonnier, Nancy (CDC/DDID/NCIRD/OD)
Subject: RE: NAS
Attachments: NASEM Response to OSTP re Coronavirus_February 6 2020.pdf

Nancy:

It is not a report. It is a letter from NAS to OSTP saying that it is important to bring together a group of experts to study the evolutionary origin the COVID19. I am attaching it here. I have no idea if it has been widely distributed and so please keep it internal.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Messonnier, Nancy (CDC/DDID/NCIRD/OD) (b) (6) >
Sent: Thursday, February 13, 2020 1:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Subject: NAS

Either you or Bob Kadlec made reference to a NAS report on the origins of SARS – COV2. (b) (5)

Thanks.
Nancy

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 15:21:22 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E]
Subject: RE: Redfield/Fauci nCoV op-ed
Attachments: Coronavirus OpEd - Redfield and Fauci - 02-06-2020.docx

Here it is.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 5, 2020 3:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6) >
Subject: FW: Redfield/Fauci nCoV op-ed

Here is the op-ed as cleared by WH.
Any issues with this?

(b) (5)

From: Brennan, Patrick (OS/ASPA) <(b) (6)>
Sent: Wednesday, February 5, 2020 3:39 PM
To: Routh, Jennifer (NIH/NIAID) [E] (b) (6); Lepore, Loretta (CDC/OD/OCS) (b) (6)
Cc: Fine, Amanda (NIH/OD) [E] (b) (6) Galatas, Kate (CDC/OD/OADC) (b) (6); Bonds, Michelle E. (CDC/OD/OADC) (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6); Campbell, Amanda (CDC/OD/OCS) (b) (6);

Stecker, Judy (OS/IOS) (b) (6); Murphy, Ryan (OS/ASPA) (b) (6)
Pratt, Michael (OS/ASPA) (b) (6); Oakley, Caitlin B. (OS/ASPA) (b) (6);
(b) (6); Hall, Bill (HHS/ASPA) <(b) (6)>; Myles, Renate (NIH/OD) [E]
(b) (6); Burklow, John (NIH/OD) [E] (b) (6); Stover, Kathy (NIH/NIAID)
[E] (b) (6)

Subject: RE: Redfield/Fauci nCoV op-ed

Attached is a tracked changes version and a clean version of what cleared the WH – they had a few sentences they would like to be added (which, in the tracked changes version, I have added comments to explain who suggested it and in some cases why), but almost all of these edits are non-substantive.

Assuming CDC and NIAID are good with these (feel free to modify the additions as needed), you all are good to pitch this as you wish – (b) (5)

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Sent: Sunday, February 2, 2020 6:11 PM
To: Lepore, Loretta (CDC/OD/OCS) <(b) (6)>
Cc: Fine, Amanda (NIH/OD) [E] (b) (6); Galatas, Kate (CDC/OD/OADC) (b) (6); Brennan, Patrick (OS/ASPA) (b) (6); Bonds, Michelle E. (CDC/OD/OADC) (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] <(b) (6)>; McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6); Campbell, Amanda (CDC/OD/OCS) (b) (6); Stecker, Judy (OS/IOS) (b) (6); Murphy, Ryan (OS/ASPA) (b) (6); Pratt, Michael (OS/ASPA) (b) (6); Oakley, Caitlin B. (OS/ASPA) (b) (6); Hall, Bill (HHS/ASPA) (b) (6); Myles, Renate (NIH/OD) [E] (b) (6); Burklow, John (NIH/OD) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6)
Subject: RE: Redfield/Fauci nCoV op-ed

All – attached is a track changes draft and a clean version with input from NIAID and Dr. Fauci.

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lepore, Loretta (CDC/OD/OCS) (b) (6)
Sent: Sunday, February 2, 2020 2:39 PM

To: Fine, Amanda (NIH/OD) [E]; Galatas, Kate (CDC/OD/OADC); Brennan, Patrick (OS/ASPA); Bonds, Michelle E. (CDC/OD/OADC); Conrad, Patricia (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS); Campbell, Amanda (CDC/OD/OCS); Stecker, Judy (OS/IOS); Murphy, Ryan (OS/ASPA); Pratt, Michael (OS/ASPA); Oakley, Caitlin B. (OS/ASPA); Hall, Bill (HHS/ASPA); Myles, Renate (NIH/OD) [E]
Subject: RE: Redfield/Fauci nCoV op-ed

Good afternoon all,

I am forwarding the op-ed drafted by CDC and reviewed by Dr. Redfield for review by Dr. Fauci and our colleagues at NIH.

Please reach out with any questions.

Best,
Loretta

From: Fine, Amanda (NIH/OD) [E] (b) (6)
Sent: Friday, January 31, 2020 6:36 PM
To: Galatas, Kate (CDC/OD/OADC) (b) (6); Brennan, Patrick (OS/ASPA) (b) (6); Bonds, Michelle E. (CDC/OD/OADC) (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6); Lepore, Loretta (CDC/OD/OCS) (b) (6)
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6); Campbell, Amanda (CDC/OD/OCS) (b) (6); Stecker, Judy (OS/IOS) (b) (6); Murphy, Ryan (OS/ASPA) (b) (6); Pratt, Michael (OS/ASPA) (b) (6); Oakley, Caitlin B. (OS/ASPA) <(b) (6)>; Hall, Bill (HHS/ASPA) <(b) (6)>; Myles, Renate (NIH/OD) [E] (b) (6)
Subject: RE: Redfield/Fauci nCoV op-ed

+ Renate Myles for awareness

From: Galatas, Kate (CDC/OD/OADC) (b) (6)
Sent: Friday, January 31, 2020 6:34 PM
To: Brennan, Patrick (OS/ASPA) <(b) (6)>; Bonds, Michelle E. (CDC/OD/OADC) (b) (6); Fine, Amanda (NIH/OD) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6); Lepore, Loretta (CDC/OD/OCS) (b) (6)
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6); Campbell, Amanda (CDC/OD/OCS) (b) (6); Stecker, Judy (OS/IOS) <(b) (6)>; Murphy, Ryan (OS/ASPA) (b) (6); Pratt, Michael (OS/ASPA) (b) (6); Oakley, Caitlin B. (OS/ASPA) (b) (6); Hall, Bill (HHS/ASPA) (b) (6)
Subject: Re: Redfield/Fauci nCoV op-ed

Hi, Patrick -
We've put this in motion — once it's cleared thru CDC, we will send back to this group so NIH comms can move thru with their editing/revisions.

Let me know if that sounds OK. We will likely not have a cleared version out of CDC until late Saturday at the earliest.

Take care,
Kate

Get [Outlook for iOS](#)

From: Brennan, Patrick (OS/ASPA) <[REDACTED] (b) (6)>
Sent: Friday, January 31, 2020 5:31:46 PM
To: Bonds, Michelle E. (CDC/OD/OADC) [REDACTED] (b) (6)>; Fine, Amanda (NIH/OD) [E] [REDACTED] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [REDACTED] (b) (6)>; Lepore, Loretta (CDC/OD/OCS) [REDACTED] (b) (6)>
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS) [REDACTED] (b) (6); Campbell, Amanda (CDC/OD/OCS) [REDACTED] (b) (6)>; Stecker, Judy (OS/IOS) [REDACTED] (b) (6); Murphy, Ryan (OS/ASPA) [REDACTED] (b) (6); Pratt, Michael (OS/ASPA) [REDACTED] (b) (6); Oakley, Caitlin B. (OS/ASPA) [REDACTED] (b) (6)>; Hall, Bill (HHS/ASPA) [REDACTED] (b) (6)>; Galatas, Kate (CDC/OD/OADC) [REDACTED] (b) (6)>
Subject: Redfield/Fauci nCoV op-ed

CDC and NIH folks,

Per some discussion after the presser, we'd like Dr. Redfield and Dr. Fauci to pen an op-ed regarding the reasons/thinking behind the policy announced today. I assume the right building blocks for it would be the remarks they made today – which I believe you all should have the copy/notes for? I have the Secretary's, which we'll be sending around/posting shortly and I'll make sure to re-up it here so you all have it.

It would be great to have a draft of this cleared to get to the WH over the weekend. (I anticipate faster-than-average clearance from them!)

Please let me know how I can help with this.

Best,
Patrick

Patrick Brennan

Director of Speechwriting

Department of Health and Human Services

Office: [REDACTED] (b) (6) | Cell [REDACTED] (b) (6)

Predecisional/deliberative communication

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 11 Feb 2020 12:54:11 +0000
To: (b) (6)
Subject: FW: Following Up If We can Be of Any Assistance

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Kadlec, Robert (OS/ASPR/IO) (b) (6) >
Sent: Tuesday, February 11, 2020 7:28 AM
To: (b) (6)
Cc: (b) (6) Elvander, Erika (OS/OGA) (b) (6); Lamana, Joseph (OS/ASPR/EMMO) <(b) (6)>; Disbrow, Gary (OS/ASPR/BARDA) (b) (6); Yeskey, Kevin (OS/ASPR/IO) (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: RE: Following Up If We can Be of Any Assistance

Dear Dr. Suzuki we heard from Jun the news that your Prime Minister gave approval for the deployment of our team. We are moving expeditiously to get them there to assist. In light of the situation and the increasing numbers of cases on the ship, (b) (5)

(b) (5)

Again, we are grateful and excited that we have the opportunity to work together.

Kanpai!

Bob

From: Kadlec, Robert (OS/ASPR/IO)

Sent: Monday, February 10, 2020 8:14 PM

To: (b) (6)

Cc: (b) (6); Elvander, Erika (OS/OGA) (b) (6); Lamana, Joseph (HHS/ASPR/OEM) (b) (6)
(b) (6)

Subject: Following Up If We can Be of Any Assistance

Dear Dr. Suzuki –

I hope this finds you in good health and expect that you are deeply involved in the events of coronavirus in your region. I understand from various communications with the MHLW that is considering ending the quarantine early and releasing passengers from the Diamond Princess, especially those who are 80 years of age or older. Given the media reports and public perception there is pressure to do this. However, as medical experts, you and I both know that days 3 – 8 are within the normal incubation period and these new positives do not likely represent shipboard transmission. As such, HHS is willing to coordinate U.S. medical experts who can engage with English language media explaining and reassuring the passengers, crew, and public.

Regarding support for the quarantine, ASPR is ready to deploy a team of 3-5 people quickly, and as many as 12 people to Japan to support as suggested in the previous call. If we can assist you and your team in managing the Americans currently in quarantine please let me know. If there is other support do let me know and ASPR will work to assist. As we've talked for the past 18 months about such a scenario, this may not be the one we envisioned, but it is a perfect case as we can clearly identify the Americans, they are in a contained area. Our mutual efforts and planning have paid unexpected dividends.

I am available to discuss via teleconference at your convenience. I am grateful for all MHLW has done to support this complicated response on top of your work supporting repatriation and domestic monitoring of your own citizens. We are grateful for Dr. Sugihara's herculean information sharing efforts and the rest of your MHLW team support during this event; it


validates of the importance of our ongoing liaison program and the long term benefits of our mutual commitment to each other's public health security

Please remain well and I look forward to see you again soon.

Best wishes and warm regards.

Dr Bob Kadlec
ASPR

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 10 Feb 2020 18:43:59 +0000
To: Brennan, Patrick (OS/ASPA)
Cc: Hall, Bill (HHS/ASPA);Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Draft of email
Attachments: 2 10 20 email - with Fauci edits.docx

Here is the document with my tracked changes. 

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Brennan, Patrick (OS/ASPA) (b) (6)
Sent: Monday, February 10, 2020 1:26 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Cc: Hall, Bill (HHS/ASPA) <Bill.Hall@HHS.GOV>
Subject: Draft of email


Dr. Fauci – below and in the attached is our proposed draft response, and then Cuccinelli's email text below for context. We're waiting on a potential detail/point or two from ASPR that may help flesh it out a bit but we'll see if we actually need it. Thank you!

<< File: 2 10 20 email.docx >>
Draft HHS response

Fellow task force members,

Thanks for your message, Ken, and I look forward to our discussion today.

(b) (5)





Looking forward to discussing more later today.

Ken

To my fellow task force members,

(b) (5)





I look forward to speaking with you all again this afternoon.

Patrick Brennan

Director of Speechwriting

Department of Health and Human Services

Office: (b) (6) | Cell: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 9 Feb 2020 23:54:27 +0000
To: (b) (6)
Subject: FW: WHO advance team on coronavirus on way to China - Tedros tweet

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Grigsby, Garrett (HHS/OS/OGA) <(b) (6)>
Sent: Sunday, February 9, 2020 6:35 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Harrison, Brian (HHS/IOS) <(b) (6)>
Cc: Kerr, Lawrence (HHS/OS/OGA) <(b) (6)>; Elvander, Erika (OS/OGA) <(b) (6)>; Zebley, Kyle (HHS/OS/OGA) <(b) (6)>; Redfield, Robert R. (CDC/OD) <(b) (6)>; Kadlec, Robert (OS/ASPR/IO) <(b) (6)>; Abram, Anna (FDA/OC) <(b) (6)>; Bright, Rick (OS/ASPR/BARDA) <(b) (6)>
Subject: RE: WHO advance team on coronavirus on way to China - Tedros tweet

Dr F,

(b) (5)

From: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Sent: Sunday, February 9, 2020 6:24 PM
To: Grigsby, Garrett (HHS/OS/OGA) <(b) (6)>; Harrison, Brian (HHS/IOS) <(b) (6)>

Cc: Kerr, Lawrence (HHS/OS/OGA) <(b) (6)>; Elvander, Erika (OS/OGA) <(b) (6)>; Zebley, Kyle (HHS/OS/OGA) <(b) (6)>; Redfield, Robert R. (CDC/OD) <(b) (6)>; Kadlec, Robert (OS/ASPR/IO) <(b) (6)>; Abram, Anna (FDA/OC) <(b) (6)>; Bright, Rick (OS/ASPR/BARDA) <(b) (6)>
Subject: RE: WHO advance team on coronavirus on way to China - Tedros tweet

(b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Grigsby, Garrett (HHS/OS/OGA) <(b) (6)>
Sent: Sunday, February 9, 2020 6:03 PM
To: Harrison, Brian (HHS/IOS) <(b) (6)>
Cc: Kerr, Lawrence (HHS/OS/OGA) <(b) (6)>; Elvander, Erika (OS/OGA) <(b) (6)>; Zebley, Kyle (HHS/OS/OGA) <(b) (6)>; Redfield, Robert R. (CDC/OD) <(b) (6)>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>; Kadlec, Robert (OS/ASPR/IO) <(b) (6)>; Abram, Anna (FDA/OC) <(b) (6)>; Bright, Rick (OS/ASPR/BARDA) <(b) (6)>
Subject: FW: WHO advance team on coronavirus on way to China - Tedros tweet

Brian – more clarity from “the horse’s mouth” on this advance trip...see below.

From: Grigsby, Garrett (HHS/OS/OGA)
Sent: Sunday, February 9, 2020 6:01 PM
To: SCHWARTLANDER, Bernhard F. <(b) (6)>
Cc: SIMONSON, Stewart <(b) (6)>
Subject: RE: WHO advance team on coronavirus on way to China - Tedros tweet

Many thanks, Bernard! I know I'll be asked, so I will pass your email up the chain...

Take care and thanks again!

From: SCHWARTLANDER, Bernhard F. (b) (6)
Sent: Sunday, February 9, 2020 5:59 PM
To: Grigsby, Garrett (HHS/OS/OGA) (b) (6)>
Cc: SIMONSON, Stewart (b) (6)
Subject: Re: WHO advance team on coronavirus on way to China - Tedros tweet

Hi Garrett,

We have three people on the way to Beijing who will work with our Chinese counterparts on finalizing the TOR and composition of the joint WHO - China mission. As you are much aware, the US has given us a number of names who will be able and willing to join such a mission. We have received similar proposals from other countries and will now match the "long list" of experts with the required specific expertise.

We are hoping to have more clarity over the coming days and will obviously keep you in the loop. The overall number will be kept at a level to make sure that the team is fully operational.

With my warmest wishes

Bernhard

Dr Bernhard Schwartländer
Chef de Cabinet
World Health Organization

On 9 Feb 2020, at 23:24, Grigsby, Garrett (HHS/OS/OGA) (b) (6)> wrote:

Bernard,

Hope you had a good weekend.

I'm reaching out to get more clarity on the WHO experts team issue – please see article below. I've heard everything from an advance group of one or two individuals to 15 people discussed in the article. I haven't heard any word about US people, and I was just with Dr Redfield late this afternoon and he was in the dark too.

Any additional information will be deeply appreciated.

Thanks!

From: Kerr, Lawrence (HHS/OS/OGA) <(b) (6)>
Sent: Sunday, February 9, 2020 5:03 PM
To: Grigsby, Garrett (HHS/OS/OGA) <(b) (6)>; Zebley, Kyle (HHS/OS/OGA) <(b) (6)>; Elvander, Erika (OS/OGA) <(b) (6)>; Tracy Carson <(b) (6)>
Subject: WHO advance team on coronavirus on way to China - Tedros tweet

February 9, 2020 / 4:01 PM / Updated an hour ago

UPDATE 1-WHO advance team on coronavirus on way to China - Tedros tweet

[Stephanie Nebehay](#)

By Stephanie Nebehay

GENEVA, Feb 9 (Reuters) - An advance team of international experts led by the World Health Organization (WHO) has left for Beijing to help investigate China's coronavirus epidemic, the Geneva-based agency said on Sunday.

WHO director-general Tedros Adhanom Ghebreyesus, who made a trip to Beijing for talks with President Xi Jinping and Chinese ministers in late January, returned with an agreement on sending an international mission.

But it has taken nearly two weeks to get the government's green light on its composition, which was not announced, other than to say that WHO veteran Dr. Bruce Aylward, a Canadian epidemiologist and emergencies expert, was heading it.

"I've just been at the airport seeing off members of an advance team for the @WHO-led #2019nCoV international expert mission to #China, led by Dr Bruce Aylward, veteran of past public health emergencies," Tedros said in a tweet from Geneva.

Dr. Sylvie Briand, who accompanied Tedros last month and stayed behind for talks with top Chinese health officials, told Reuters last week that they were discussing a list of experts with China.

"Because it is a joint mission, they need to be on board, it's not just an international group going there. We have about 15 people," said Briand, director of Global Infectious Hazard Preparedness at WHO.

China raised the death toll from the coronavirus outbreak to 811 on Sunday, passing the number killed globally by the SARS epidemic, as authorities made plans for millions of people returning to work after an extended Lunar New Year break.

The virus, which has spread to two dozen countries, has killed some 2% of more than 37,550 cases worldwide, with 99 percent of infections in China, WHO figures show.

The WHO declared the outbreak a global emergency on Jan. 30, days after the Chinese central government imposed a lockdown on 60 million people in Hubei province and its capital Wuhan, epicentre of the virus that emerged in December in a seafood market.

Tedros said on Saturday that he hoped the team would include experts from the U.S. Centers for Disease Control (CDC).

"It has to be meaningful on the ground," Lawrence Gostin, professor of global health law at Georgetown Law, said in an interview in Geneva this week.

Gostin called for a "genuine partnership with transparent flows of information and accountability for the response", adding that there should be a strong CDC presence.

"CDC has got no peer in terms of its experience and technical expertise in dealing with international outbreaks," he said.

"But the other benefit is the smart diplomacy, what it could signal is that despite all of our differences in ideology, trade, politics, that when faced with a common threat to humanity, we come together as a human community to tackle it," Gostin said.

Reporting by Stephanie Nebehay; Editing by Pravin Char, Kirsten Donovan

Our Standards:[The Thomson Reuters Trust Principles.](#)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:55:22 +0000
To: Shapiro, Neil (NIH/OD) [E]; Collins, Francis (NIH/OD) [E]; Tabak, Lawrence (NIH/OD) [E]; Johnson, Alfred (NIH/OD) [E]; Hallett, Adrienne (NIH/OD) [E]
Cc: Shaya, Cecile (NIH/OD) [E]
Subject: RE: Coronavirus - HHS Supplemental Table - Close Hold

(b) (5)

From: Shapiro, Neil (NIH/OD) [E] (b) (6)
Sent: Thursday, February 6, 2020 8:08 PM
To: Collins, Francis (NIH/OD) [E] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Johnson, Alfred (NIH/OD) [E] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Shaya, Cecile (NIH/OD) [E] (b) (6)
Subject: RE: Coronavirus - HHS Supplemental Table - Close Hold

I'll ask, unless Tony knows. (b) (5)

Neil

From: Collins, Francis (NIH/OD) [E] (b) (6)
Sent: Thursday, February 6, 2020 4:59 PM
To: Shapiro, Neil (NIH/OD) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Johnson, Alfred (NIH/OD) [E] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Shaya, Cecile (NIH/OD) [E] (b) (6)>
Subject: RE: Coronavirus - HHS Supplemental Table - Close Hold

(b) (5)

FC

From: Shapiro, Neil (NIH/OD) [E] (b) (6)>
Sent: Thursday, February 6, 2020 3:22 PM
To: Collins, Francis (NIH/OD) [E] (b) (6); Tabak, Lawrence (NIH/OD) [E] (b) (6)>; Johnson, Alfred (NIH/OD) [E] (b) (6)>; Hallett, Adrienne (NIH/OD) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Shaya, Cecile (NIH/OD) [E] (b) (6)
Subject: FW: Coronavirus - HHS Supplemental Table - Close Hold
Importance: High

ASFR provided the pdf attachment and the explanation below. They emphasized on the phone too that this is very close hold.

(b) (5),
(b) (5)

Neil

From: Cabezas, Miriam (HHS/ASFR) (b) (6)>
Sent: Thursday, February 6, 2020 2:32 PM
To: Kelly, Alison (CDC/OCOO/OFR/OA) (b) (6)>; Berger, Sherri (CDC/OCOO/OD) (b) (6); Shapiro, Neil (NIH/OD) [E] (b) (6)>; Shaya, Cecile (NIH/OD) [E] (b) (6)>; Petillo, Jay (OS/ASPR/MFHC) (b) (6)>; Dubay, Johanna (OS/ASPR/MFHC) (b) (6)
Cc: Goyle, Suraj (OS/ASFR) <(b) (6)>; Falisi, Angela (OS/ASFR) (b) (6)>; White, RaeShawn (OS/ASFR) (b) (6)>; Cormier, Justin (HHS/ASFR) (b) (6)>
Subject: Coronavirus - HHS Supplemental Table - Close Hold

Information in this email is close hold.

Good afternoon –


Attached you will find CDC, ASPR, and NIH specific totals that were provided to OMB last night. We want to make sure you have awareness of the activities that are identified across these three agencies. Let us know if you have any questions. This information should not be shared broadly.

Miriam

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 7 Feb 2020 03:38:07 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: RE: ** Time-Sensitive Clearance ** DUE BY 3:30 TODAY- Coronavirus - Minister Ma of China Response Letter - 00430215

Please take care of this on my behalf. Thanks.

From: Marston, Hilary (NIH/NIAID) [E] (b) (6)
Sent: Thursday, February 6, 2020 3:11 PM
To: Harris, Kara (NIH/NIAID) [E] <(b) (6)>; Handley, Gray (NIH/NIAID) [E] <(b) (6)>; Lerner, Andrea (NIH/NIAID) [E] (b) (6)>; Eisinger, Robert (NIH/NIAID) [E] <(b) (6)>; Harper, Jill (NIH/NIAID) [E] (b) (6)>; McGowan, John J. (NIH/NIAID) [E] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] (b) (6)>
Cc: NIAID OCGR Correspondence <NIAIDOCGRCorrespondence@mail.nih.gov>; Gilles, Sharon (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Subject: RE: ** Time-Sensitive Clearance ** DUE BY 3:30 TODAY- Coronavirus - Minister Ma of China Response Letter - 00430215



From: Harris, Kara (NIH/NIAID) [E] (b) (6)>
Sent: Thursday, February 6, 2020 3:00 PM
To: Handley, Gray (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)>; Lerner, Andrea (NIH/NIAID) [E] (b) (6); Eisinger, Robert (NIH/NIAID) [E] (b) (6); Harper, Jill (NIH/NIAID) [E] <(b) (6)>; McGowan, John J. (NIH/NIAID) [E] <(b) (6)>; Billet, Courtney (NIH/NIAID) [E] (b) (6)>; Auchincloss, Hugh (NIH/NIAID) [E] <(b) (6)>
Cc: NIAID OCGR Correspondence <NIAIDOCGRCorrespondence@mail.nih.gov>; Gilles, Sharon (NIH/NIAID) [E] (b) (6)

Subject: FW: ** Time-Sensitive Clearance ** DUE BY 3:30 TODAY- Coronavirus - Minister Ma of China Response Letter - 00430215

Importance: High

All –

Please see the note below from Exec Sec. Please provide any comments to NIAID OCGR Correspondence by 3:30 p.m. Please note – Exec Sec is looking for **show-stopping comments only**.

Thank you,
Kara

From: Malliou, Ekaterini (OS/IOS) (b) (6)>
Sent: Thursday, February 6, 2020 2:25 PM
To: Stannard, Paula (HHS/IOS) <(b) (6)>; Hoffmann, Lauren (CDC/OD/OCS) (b) (6)>; Clark, Cynthia K. (CDC/OD/OCS) (b) (6)>; Stimson, Brian (HHS/OGC) (b) (6)>; Chang, William (HHS/OGC) (b) (6)>; Barry, Daniel J (HHS/OGC) <(b) (6)>; Shuy, Bryan (OS/ASPR/IO) (b) (6)>; Bird, Catherine (OS/OGC) (b) (6) OS OGC-IO <ControlDesk.OGCIO@hhs.gov>; ASPR Exec Sec (OS/ASPR) <ASPRExecSec@hhs.gov>
Cc: Steele, Danielle (HHS/IOS) (b) (6)>; Agnew, Ann (HHS/IOS) (b) (6)>; Hawkins, Jamar (HHS/OS) (b) (6)>; Horska, Katerina (HHS/IOS) (b) (6)>; Varnado, Martina (FDA/OC) (b) (6)>; Zebley, Kyle (HHS/OS/OGA) (b) (6)>; Allen-Gifford, Patrice (NIH/OD) [E] (b) (6)>
Subject: Clearance Due 6pm (2/6): ** Time-Sensitive ** Coronavirus - Minister Ma of China Response Letter - 00430215

Please find attached for your clearance a response to Minister Ma’s letter to the Secretary, and a recent conversation with him. (b) (5)

Please note that the Secretary has already reviewed and edited the attached response

We appreciate your expedited review and clearance by 6pm today, 2/6.

Thank you,

Kat

Ekaterini (Kat) Malliou, DrPH, MPH
Senior Policy Coordinator
Immediate Office of the Secretary, U.S. Department of Health and Human Services
200 Independence Ave SW, Suite 619H, Washington, DC 20201, USA
Tel: (b) (6) Cell: (b) (6), Email: (b) (6)

From: (b) (6)
Sent: Thu, 6 Feb 2020 18:56:07 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E]
Subject: Re: FROM CAITLIN OAKLEY - Atlantic reporter responded

Please schedule call for tomorrow.

On Feb 6, 2020, at 4:17 PM, Conrad, Patricia (NIH/NIAID) [E]
(b) (6) wrote:

See below – the reporter responded to Caitlyn – not Courtney – he can speak today or tomorrow. Do you want to call tonight or have me schedule for tomorrow?

Tomorrow is quite full but can make it happen...let me know

Yes, happy to talk today or tomorrow.
I'm at (b) (6)

If Dr. Fauci is available, that would be great.

Best,

Peter Nicholas

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It

should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Oakley, Caitlin B. (OS/ASPA) <(b) (6)>
Sent: Thursday, February 6, 2020 4:12 PM
To: Billet, Courtney (NIH/NIAID) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Subject: FW: follow up re: Coronavirus story

Caitlin B. Oakley
Deputy Assistant Secretary, National Spokesperson
Office of the Assistant Secretary for Public Affairs
U.S. Department of Health and Human Services
(b) (6)

From: Peter Nicholas <pnicholas@theatlantic.com>
Sent: Thursday, February 6, 2020 3:00 PM
To: Oakley, Caitlin B. (OS/ASPA) <(b) (6)>
Subject: Re: follow up re: Coronavirus story

Hi,

Yes, happy to talk today or tomorrow.
I'm at (b) (6). If Dr. Fauci is available, that would be great.

Best,

Peter

On Thu, Feb 6, 2020 at 11:09 AM Oakley, Caitlin B. (OS/ASPA) <(b) (6)> wrote:

Following up on this...does today work?

And I know Dr. Fauci's office is trying to get in contact as well. He's a member of the taskforce. Can we make this happen?

Caitlin B. Oakley
Deputy Assistant Secretary, National Spokesperson
Office of the Assistant Secretary for Public Affairs
U.S. Department of Health and Human Services
(b) (6)

From: Oakley, Caitlin B. (OS/ASPA)
Sent: Wednesday, February 5, 2020 3:55 PM
To: pnicholas@theatlantic.com
Cc: Hall, Bill (HHS/ASPA) (b) (6)>
Subject: follow up re: Coronavirus story

Peter—Thanks for the chat yesterday. Have a few folks that I'd like to get you on the phone with about your piece. Would you have time to chat with Bill Hall and I later today?

And when is your deadline for the piece?

Talk soon,

Caitlin B. Oakley

Deputy Assistant Secretary, National Spokesperson
Office of the Assistant Secretary for Public Affairs
U.S. Department of Health and Human Services

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 15:21:22 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E]
Subject: RE: Redfield/Fauci nCoV op-ed
Attachments: Coronavirus OpEd - Redfield and Fauci - 02-06-2020.docx

Here it is.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, February 5, 2020 3:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6) >
Subject: FW: Redfield/Fauci nCoV op-ed

Here is the op-ed as cleared by WH.
Any issues with this?

(b) (5)

From: Brennan, Patrick (OS/ASPA) <(b) (6)>
Sent: Wednesday, February 5, 2020 3:39 PM
To: Routh, Jennifer (NIH/NIAID) [E] (b) (6); Lepore, Loretta (CDC/OD/OCS) (b) (6)
Cc: Fine, Amanda (NIH/OD) [E] (b) (6) Galatas, Kate (CDC/OD/OADC) (b) (6); Bonds, Michelle E. (CDC/OD/OADC) (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6); McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6); Campbell, Amanda (CDC/OD/OCS) (b) (6);

Stecker, Judy (OS/IOS) (b) (6); Murphy, Ryan (OS/ASPA) (b) (6)
Pratt, Michael (OS/ASPA) (b) (6); Oakley, Caitlin B. (OS/ASPA) (b) (6);
(b) (6); Hall, Bill (HHS/ASPA) <(b) (6)>; Myles, Renate (NIH/OD) [E]
(b) (6); Burklow, John (NIH/OD) [E] (b) (6); Stover, Kathy (NIH/NIAID)
[E] (b) (6)

Subject: RE: Redfield/Fauci nCoV op-ed

Attached is a tracked changes version and a clean version of what cleared the WH – they had a few sentences they would like to be added (which, in the tracked changes version, I have added comments to explain who suggested it and in some cases why), but almost all of these edits are non-substantive.

Assuming CDC and NIAID are good with these (feel free to modify the additions as needed), you all are good to pitch this as you wish – (b) (5)

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Sent: Sunday, February 2, 2020 6:11 PM
To: Lepore, Loretta (CDC/OD/OCS) <(b) (6)>
Cc: Fine, Amanda (NIH/OD) [E] (b) (6); Galatas, Kate (CDC/OD/OADC) (b) (6); Brennan, Patrick (OS/ASPA) (b) (6); Bonds, Michelle E. (CDC/OD/OADC) (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] <(b) (6)>; McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6); Campbell, Amanda (CDC/OD/OCS) (b) (6); Stecker, Judy (OS/IOS) (b) (6); Murphy, Ryan (OS/ASPA) (b) (6); Pratt, Michael (OS/ASPA) (b) (6); Oakley, Caitlin B. (OS/ASPA) (b) (6); Hall, Bill (HHS/ASPA) (b) (6); Myles, Renate (NIH/OD) [E] (b) (6); Burklow, John (NIH/OD) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6)
Subject: RE: Redfield/Fauci nCoV op-ed

All – attached is a track changes draft and a clean version with input from NIAID and Dr. Fauci.

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lepore, Loretta (CDC/OD/OCS) (b) (6)
Sent: Sunday, February 2, 2020 2:39 PM

To: Fine, Amanda (NIH/OD) [E]; Galatas, Kate (CDC/OD/OADC); Brennan, Patrick (OS/ASPA); Bonds, Michelle E. (CDC/OD/OADC); Conrad, Patricia (NIH/NIAID) [E]; Billet, Courtney (NIH/NIAID) [E]
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS); Campbell, Amanda (CDC/OD/OCS); Stecker, Judy (OS/IOS); Murphy, Ryan (OS/ASPA); Pratt, Michael (OS/ASPA); Oakley, Caitlin B. (OS/ASPA); Hall, Bill (HHS/ASPA); Myles, Renate (NIH/OD) [E]
Subject: RE: Redfield/Fauci nCoV op-ed

Good afternoon all,

I am forwarding the op-ed drafted by CDC and reviewed by Dr. Redfield for review by Dr. Fauci and our colleagues at NIH.

Please reach out with any questions.

Best,
Loretta

From: Fine, Amanda (NIH/OD) [E] (b) (6)
Sent: Friday, January 31, 2020 6:36 PM
To: Galatas, Kate (CDC/OD/OADC) (b) (6); Brennan, Patrick (OS/ASPA) (b) (6); Bonds, Michelle E. (CDC/OD/OADC) (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6); Lepore, Loretta (CDC/OD/OCS) (b) (6)
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6); Campbell, Amanda (CDC/OD/OCS) (b) (6); Stecker, Judy (OS/IOS) (b) (6); Murphy, Ryan (OS/ASPA) (b) (6); Pratt, Michael (OS/ASPA) (b) (6); Oakley, Caitlin B. (OS/ASPA) <(b) (6)>; Hall, Bill (HHS/ASPA) <(b) (6)>; Myles, Renate (NIH/OD) [E] (b) (6)
Subject: RE: Redfield/Fauci nCoV op-ed

+ Renate Myles for awareness

From: Galatas, Kate (CDC/OD/OADC) (b) (6)
Sent: Friday, January 31, 2020 6:34 PM
To: Brennan, Patrick (OS/ASPA) <(b) (6)>; Bonds, Michelle E. (CDC/OD/OADC) (b) (6); Fine, Amanda (NIH/OD) [E] <(b) (6)>; Conrad, Patricia (NIH/NIAID) [E] (b) (6); Billet, Courtney (NIH/NIAID) [E] (b) (6); Lepore, Loretta (CDC/OD/OCS) (b) (6)
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS) (b) (6); Campbell, Amanda (CDC/OD/OCS) (b) (6); Stecker, Judy (OS/IOS) <(b) (6)>; Murphy, Ryan (OS/ASPA) (b) (6); Pratt, Michael (OS/ASPA) (b) (6); Oakley, Caitlin B. (OS/ASPA) (b) (6); Hall, Bill (HHS/ASPA) (b) (6)
Subject: Re: Redfield/Fauci nCoV op-ed

Hi, Patrick -
We've put this in motion — once it's cleared thru CDC, we will send back to this group so NIH comms can move thru with their editing/revisions.

Let me know if that sounds OK. We will likely not have a cleared version out of CDC until late Saturday at the earliest.

Take care,
Kate

Get [Outlook for iOS](#)

From: Brennan, Patrick (OS/ASPA) <[REDACTED] (b) (6)>
Sent: Friday, January 31, 2020 5:31:46 PM
To: Bonds, Michelle E. (CDC/OD/OADC) [REDACTED] (b) (6)>; Fine, Amanda (NIH/OD) [E] [REDACTED] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <[REDACTED] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [REDACTED] (b) (6)>; Lepore, Loretta (CDC/OD/OCS) [REDACTED] (b) (6)>
Cc: McGowan, Robert (Kyle) (CDC/OD/OCS) [REDACTED] (b) (6); Campbell, Amanda (CDC/OD/OCS) [REDACTED] (b) (6)>; Stecker, Judy (OS/IOS) [REDACTED] (b) (6); Murphy, Ryan (OS/ASPA) [REDACTED] (b) (6); Pratt, Michael (OS/ASPA) [REDACTED] (b) (6); Oakley, Caitlin B. (OS/ASPA) [REDACTED] (b) (6)>; Hall, Bill (HHS/ASPA) [REDACTED] (b) (6)>; Galatas, Kate (CDC/OD/OADC) [REDACTED] (b) (6)>
Subject: Redfield/Fauci nCoV op-ed

CDC and NIH folks,

Per some discussion after the presser, we'd like Dr. Redfield and Dr. Fauci to pen an op-ed regarding the reasons/thinking behind the policy announced today. I assume the right building blocks for it would be the remarks they made today – which I believe you all should have the copy/notes for? I have the Secretary's, which we'll be sending around/posting shortly and I'll make sure to re-up it here so you all have it.

It would be great to have a draft of this cleared to get to the WH over the weekend. (I anticipate faster-than-average clearance from them!)

Please let me know how I can help with this.

Best,
Patrick

Patrick Brennan
Director of Speechwriting
Department of Health and Human Services
Office: [REDACTED] (b) (6) | Cell [REDACTED] (b) (6)

Predecisional/deliberative communication

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 14:54:16 +0000
To: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: ASF: rAzar/Pompeo op-ed
Attachments: 2 5 20 pompeo azar op-ed State - with Fauci tracked edits..docx

Here are my tracked edits. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] <(b) (6)>
Sent: Thursday, February 6, 2020 7:31 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6)>
Subject: ASF: rAzar/Pompeo op-ed

Sending to all of you simultaneously, in the interest of time. Our comments are due back at noon.

From: "Brennan, Patrick (OS/ASPA)" <(b) (6)>
Date: Thursday, February 6, 2020 at 1:23:26 AM
To: "Routh, Jennifer (NIH/NIAID) [E]" (b) (6)>, "Bonds, Michelle E. (CDC/OD/OADC)" (b) (6), "Galatas, Kate (CDC/OD/OADC)" (b) (6)>, "Fine, Amanda (NIH/OD) [E]" (b) (6)>, "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>, "Kane, Eileen (OS/ASPR/OEA)" (b) (6)>, "Michael, Gretchen (OS/ASPR/OEA)" (b) (6), "Billet, Courtney (NIH/NIAID) [E]" (b) (6)>, "Lepore, Loretta (CDC/OD/OCS)" (b) (6), "McGowan, Robert (Kyle) (CDC/OD/OCS)" (b) (6), "Campbell, Amanda (CDC/OD/OCS)" (b) (6)>, "Zebley, Kyle (HHS/OS/OGA)"

(b) (6), "Chang, William (HHS/OGC)" (b) (6), "Keveney, Sean (HHS/OGC)" (b) (6), "Grigsby, Garrett (HHS/OS/OGA)" (b) (6)
Cc: "Billet, Courtney (NIH/NIAID) [E]" (b) (6), "ASPA-Deputies" <ASPA-Deputies@hhs.gov>

Subject: For review by noon Thurs: revised Azar/Pompeo op-ed

Hi all,

Attached is a largely new draft of the Azar/Pompeo op-ed that (b) (5)

(b) (5) I've made a couple additions and edits to their new version, which I've tracked/flagged.

NIAID, CDC, and OGC, please let me know if this looks OK by noon tomorrow. Thank you!

Best,

Patrick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 14:24:54 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Stover, Kathy (NIH/NIAID) [E]
Subject: RE: ASF: for review, Azar coronavirus presser remarks
Attachments: Secretary's remarks with minor Fauci edits.docx

Here are my edits for Azar's press comments

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Billet, Courtney (NIH/NIAID) [E] (b) (6)
Sent: Thursday, February 6, 2020 7:29 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] (b) (6); Routh, Jennifer (NIH/NIAID) [E] (b) (6); Marston, Hilary (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] (b) (6)
Subject: ASF: for review, Azar coronavirus presser remarks

Pls see Secretary's remarks for press conf and let us know if anything glaring needs to be fixed.

They also would like talking points from us, covering what you would say. These are really just a placeholder. We could resubmit what we sent last time. Is there anything new you would anticipate saying?

From: "Brennan, Patrick (OS/ASPA)" (b) (6)>
Date: Wednesday, February 5, 2020 at 11:25:33 PM
To: "Routh, Jennifer (NIH/NIAID) [E]" (b) (6)>, "Bonds, Michelle E. (CDC/OD/OADC)" (b) (6)>, "Galatas, Kate (CDC/OD/OADC)" (b) (6), "Fine, Amanda (NIH/OD) [E]" (b) (6)>, "Conrad, Patricia (NIH/NIAID) [E]" (b) (6)>, "Kane, Eileen

(OS/ASPR/OEA)" (b) (6)>, "Michael, Gretchen (OS/ASPR/OEA)"
(b) (6)>, "Billet, Courtney (NIH/NIAID) [E]" < (b) (6), "Steele,
Danielle (HHS/IOS)" (b) (6)>, "Arbes, Sarah (HHS/ASL)" (b) (6)>,
"Moughalian, Jen (HHS/ASFR)" < (b) (6)>, "Shuy, Caitrin (HHS/ASFR)"
(b) (6), "Caliguri, Laura (FDA/OC)" (b) (6)>, "Janik, Heather
(FDA/OC)" (b) (6)>, "Lepore, Loretta (CDC/OD/OCS)" (b) (6),
"McGowan, Robert (Kyle) (CDC/OD/OCS)" (b) (6)>, "Campbell, Amanda (CDC/OD/OCS)"
(b) (6), "Zebley, Kyle (HHS/OS/OGA)" (b) (6), "Chang, William (HHS/OGC)"
(b) (6)>, "Keveney, Sean (HHS/OGC)" (b) (6)>, "Pence, Laura
(HHS/ASL)" (b) (6)"Grigsby, Garrett (HHS/OS/OGA)" (b) (6)>
Cc: "Billet, Courtney (NIH/NIAID) [E]" (b) (6)>, "Stover, Kathy (NIH/NIAID) [E]"
(b) (6)>, "ASPA-Deputies" <ASPA-Deputies@hhs.gov>

Subject: For review by 11 AM Thurs: Sec. Azar coronavirus presser remarks

Hi all,

Attached are draft remarks for the Secretary to deliver tomorrow evening at the scheduled press conference on coronavirus – after which the plan is for Dr. Redfield and then Dr. Fauci, and then whoever from State and DHS (I think?) to speak.

Can CDC, NIAID, OGC, FDA, and ASPR let me know if this looks OK by 11 AM tomorrow?

And once CDC and NIAID have their draft TPs, it would be great to see those as well.

Thank you!

- Patrick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 03:59:18 +0000
To: Grigsby, Garrett (HHS/OS/OGA); Lane, Cliff (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]; Zebley, Kyle (HHS/OS/OGA); Kerr, Lawrence (HHS/OS/OGA); Burr, Mara (HHS/OS/OGA); Levine, Maya (OS/OGA); Mciff, Colin (HHS/OS/OGA); Arboleda, Nelson (HHS/OS/OGA); Alexander, Thomas (OS/OGA)
Subject: RE: Coronavirus collaborating center

Yes. Thanks you.

-----Original Message-----

From: Grigsby, Garrett (HHS/OS/OGA) (b) (6) >
Sent: Wednesday, February 5, 2020 8:42 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >; Lane, Cliff (NIH/NIAID) [E] (b) (6) >
Cc: Marston, Hilary (NIH/NIAID) [E] (b) (6) >; Zebley, Kyle (HHS/OS/OGA) (b) (6) >; Kerr, Lawrence (HHS/OS/OGA) (b) (6) >; Burr, Mara (HHS/OS/OGA) (b) (6) >; Levine, Maya (OS/OGA) (b) (6) >; Mciff, Colin (HHS/OS/OGA) <(b) (6) >; Arboleda, Nelson (HHS/OS/OGA) (b) (6) >; Alexander, Thomas (OS/OGA) (b) (6) >
Subject: FW: Coronavirus collaborating center
Importance: High

Drs F & L,

Confirming that you want me to reply in the affirmative asap...?

-----Original Message-----

From: Lamourelle, Gabrielle (HHS/OS/OGA) (b) (6) >
Sent: Wednesday, February 5, 2020 6:50 AM
To: Grigsby, Garrett (HHS/OS/OGA) <(b) (6) >; Mciff, Colin (HHS/OS/OGA) (b) (6) >; Kerr, Lawrence (HHS/OS/OGA) <(b) (6) >; Burr, Mara (HHS/OS/OGA) (b) (6) >; Elvander, Erika (OS/OGA) (b) (6) >
Cc: Tracy Carson (b) (6) >; Smith, Steven T (Geneva) (b) (6) >; Stewart, Jessica L. (HHS/OS/OGA) <(b) (6) >; Levine, Maya (OS/OGA) (b) (6) >; Wood, Rachel (HHS/OS/OGA) (b) (6) >; Fernandez, Jose (OS/OGA) (b) (6) >
Subject: FW: Coronavirus collaborating center
Importance: High

Dear Garrett and all,

I have received the hard copy of the attached letter from Matias Tuler (WHO Collaborating Centers team) with the request that we review and provide a reply as quickly as possible. The letter, as usual form, says they will go forward in 8 weeks if they hear no objection from us.

Given the coronavirus situation, (b) (6)

If you have any questions, let me know.

Thank you,
Gabrielle

-----Original Message-----

From: TULER, Matias (b) (6)
Sent: Wednesday, February 5, 2020 9:35 AM

To: Lamourelle, Gabrielle (HHS/OS/OGA) <[REDACTED] (b) (6)>
Cc: OGA Multilateral <OGAmultilateral@hhs.gov>
Subject: RE: Coronavirus collaborating center

Dear Gabrielle,

Many thanks for the email.

I sent you an email with the letter just after we talked. I do not know if you received it. I am attaching the letter to this email again, just in case.

Thank you very much in advance.

Best regards,

Matias

Matias Tuler

Programme Manager

WHO Collaborating Centres, and WHO Expert Advisory Panels and Committees World Health Organization

Geneva , Switzerland

Office: [REDACTED] (b) (6)

Web: <http://www.who.int/collaboratingcentres/information/en/>
http://www.who.int/about/collaborations/expert_panels/en/

Follow WHO on Facebook, Twitter, YouTube, Instagram

-----Original Message-----

From: Lamourelle, Gabrielle (HHS/OS/OGA) <[REDACTED] (b) (6)>
Sent: Wednesday, February 5, 2020 9:17
To: TULER, Matias <[REDACTED] (b) (6)>
Cc: OGA Multilateral <OGAmultilateral@hhs.gov>
Subject: Coronavirus collaborating center

Dear Matias,

Thank you for sharing the hard copy of the Coronavirus collaborating center letter. Please send me an electronic copy as well and I will send back immediately to our office for a rapid reply.

With best wishes,

Gabrielle Lamourelle

Deputy Director, Multilateral Relations

HHS Office of Global Affairs

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 6 Feb 2020 02:55:19 +0000
To: Kerr, Lawrence (HHS/OS/OGA)
Cc: Grigsby, Garrett (HHS/OS/OGA)
Subject: RE: Spoke with Soumya re: evolutionary origin of nCoV

I do not see any problem with your doing this. Go for it.

Best,
Tony

From: Kerr, Lawrence (HHS/OS/OGA) (b) (6) >
Sent: Wednesday, February 5, 2020 7:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Grigsby, Garrett (HHS/OS/OGA) (b) (6) >
Subject: Spoke with Soumya re: evolutionary origin of nCoV

Dr. Fauci,



I welcome your advice please. Much thanks,

Larry